Table of Contents
The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities nor do they seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. |
Proceeds to | ||||||||||||||||||||||||
HCA Inc.(1) | ||||||||||||||||||||||||
Public offering price(1) | Underwriting discount | (before expenses) | ||||||||||||||||||||||
Per note | Total | Per note | Total | Per note | Total | |||||||||||||||||||
% Senior Secured Notes due 2020 | % | $ | % | $ | % | $ | ||||||||||||||||||
% Senior Notes due 2022 | % | $ | % | $ | % | $ | ||||||||||||||||||
(1) | Plus accrued interest, if any, from , 2011. |
J.P. Morgan | Barclays Capital | BofA Merrill Lynch | Citi | Deutsche Bank Securities | Wells Fargo Securities |
Prospectus Supplement | Page | |||
S-1 | ||||
S-21 | ||||
S-36 | ||||
S-37 | ||||
S-39 | ||||
S-49 | ||||
S-61 | ||||
S-124 | ||||
S-144 | ||||
S-150 | ||||
S-152 | ||||
S-156 | ||||
S-156 | ||||
S-156 | ||||
Prospectus | Page | |||
About This Prospectus | 1 | |||
Where You Can Find More Information | 1 | |||
Incorporation By Reference | 1 | |||
Forward-Looking Statements | 2 | |||
Our Company | 4 | |||
Risk Factors | 5 | |||
Use of Proceeds | 5 | |||
Ratio of Earnings to Fixed Charges | 5 | |||
Description of Debt Securities and Guarantees | 6 | |||
Plan of Distribution | 22 | |||
Legal Matters | 23 | |||
Experts | 23 | |||
S-i
Table of Contents
S-ii
Table of Contents
S-iii
Table of Contents
S-1
Table of Contents
S-2
Table of Contents
S-3
Table of Contents
S-4
Table of Contents
S-5
Table of Contents
S-6
Table of Contents
S-7
Table of Contents
(1) | In connection with the Corporate Reorganization, HCA Holdings, Inc. became a guarantor of all of HCA Inc.’s then-outstanding secured notes but is not subject to the covenants that apply to HCA Inc. or HCA Inc.’s restricted subsidiaries under those notes. | |
(2) | Consists of (i) a $2.000 billion asset-based revolving credit facility maturing on November 16, 2012 (the “asset-based revolving credit facility”) ($1.166 billion outstanding at March 31, 2011 as adjusted to give effect to the June redemptions); (ii) a $2.000 billion senior secured revolving credit facility maturing on November 17, 2015 (the “senior secured revolving credit facility”) (none outstanding at March 31, 2011, without giving effect to outstanding letters of credit); (iii) a $487 million senior secured term loanA-1 facility maturing on November 17, 2012; (iv) a $594 million senior secured term loanA-2 facility maturing on May 2, 2016; (v) a $1.689 billion senior secured term loan B-1 facility maturing on November 17, 2013; (vi) a $2.000 billion senior secured term loan B-2 facility maturing on March 31, 2017; (vii) a $2.373 billion senior secured term loan B-3 facility maturing on May 1, 2018; and (viii) a €291 million, or $411 million-equivalent, senior secured European term loan facility maturing on November 17, 2013. We refer to the facilities described under (ii) through (viii) above, collectively, as the “cash flow credit facility” and, together with the asset-based revolving credit facility, the “senior secured credit facilities.” Does not give effect to amounts that may be drawn under the revolving credit facility to fund our acquisition of HCA-HealthONE LLC, if consummated. See “Summary—Recent developments.” | |
(3) | Consists of (i) $1.500 billion aggregate principal amount of 81/2% first lien notes due 2019 that HCA Inc. issued in April 2009 (the “April 2009 first lien notes”); (ii) $1.250 billion aggregate principal amount of 77/8% first lien notes due 2020 that HCA Inc. issued in August 2009 (the “August 2009 first lien notes”), (iii) $1.400 billion aggregate principal amount of 71/4% first lien notes due 2020 that HCA Inc. issued in March 2010 (the “March 2010 first lien notes” and, collectively with the April 2009 first lien notes and the August 2009 first lien notes, the “first lien notes”) and (iv) $74 million of unamortized debt discounts that reduce the existing indebtedness. | |
(4) | Consists of (i) $3.200 billion aggregate principal amount of 91/4% second lien notes due 2016, (ii) $1.578 billion of 95/8%/103/8% second lien toggle notes due 2016 ($900 million of which are intended to be redeemed with the net proceeds from this offering), (iii) $310 million aggregate principal amount of 97/8% second lien notes due 2017 ($108.5 million of which were redeemed in the June redemptions), and (iv) $6 million of unamortized debt discounts that reduce the existing indebtedness. We refer to the notes issued in (i) through (iii) above, collectively as the “second lien notes” and, together with the first lien notes, the “existing secured notes.” | |
(5) | Consists of (i) an aggregate principal amount of $246 million medium-term notes with maturities ranging from 2014 to 2025 and a weighted average interest rate of 8.28%; (ii) an aggregate principal amount of $886 million debentures with |
S-8
Table of Contents
maturities ranging from 2015 to 2095 and a weighted average interest rate of 7.55%; (iii) an aggregate principal amount of $4.694 billion senior notes with maturities ranging from 2012 to 2033 and a weighted average interest rate of 6.54%; (iv) $314 million of secured debt, which represents capital leases and other secured debt with a weighted average interest rate of 7.12%; and (v) $9 million of unamortized debt discounts that reduce the existing indebtedness. For more information regarding our unsecured and other indebtedness, see “Description of other indebtedness.” | ||
(6) | The cash flow credit facility and the first lien notes are secured by first-priority liens, and the second lien notes and related guarantees are secured by second-priority liens, on substantially all the capital stock of Healthtrust, Inc. —The Hospital Company and the first-tier subsidiaries of the subsidiary guarantors (but limited to 65% of the voting stock of any such first-tier subsidiary that is a foreign subsidiary), subject to certain exceptions. | |
(7) | Includes subsidiaries which are designated as “restricted subsidiaries” under HCA Inc.’s indenture dated as of December 16, 1993, certain of their wholly owned subsidiaries formed in connection with the asset-based revolving credit facility and certain excluded subsidiaries (non-material subsidiaries). |
S-9
Table of Contents
Issuer | HCA Inc. | |
Secured Notes | % senior secured notes due 2020. | |
Maturity Date | The secured notes will mature on , 2020. | |
Interest Rate | Interest on the secured notes will be payable in cash and will accrue at a rate of % per annum. | |
Interest Payment Dates | February 15 and August 15, commencing on February 15, 2012. Interest will accrue from , 2011. | |
Ranking | The secured notes will be the Issuer’s senior obligations and will: | |
• rank senior in right of payment to any of its future subordinated indebtedness; | ||
• rank equally in right of payment with any of its existing and future senior indebtedness; | ||
• be effectively senior in right of payment to indebtedness under the second lien notes to the extent of the collateral securing such indebtedness and to any unsecured indebtedness; | ||
• be effectively equal in right of payment with indebtedness under the cash flow credit facility and the first lien notes to the extent of the collateral (other than certain European collateral securing the senior secured European term loan facility) securing such indebtedness; | ||
• be effectively subordinated in right of payment to all indebtedness under the asset-based revolving credit facility to the extent of the shared collateral securing such indebtedness; and | ||
• be effectively subordinated in right of payment to all existing and future indebtedness and other liabilities of our non-guarantor subsidiaries (other than indebtedness and liabilities owed to us or one of our guarantor subsidiaries). | ||
As of March 31, 2011, on an as adjusted basis after giving effect to the June redemptions and the notes offered hereby and the use of proceeds therefrom as described under “Use of proceeds”: | ||
• the secured notes and related guarantees would have been effectively senior in right of payment to $4.080 billion of second lien notes, effectively equal in right of payment to approximately |
S-10
Table of Contents
$7.143 billion of senior secured indebtedness under the cash flow credit facility (other than our senior secured European term loan facility), $4.150 billion of first lien notes and approximately $133 million of other secured debt, and effectively junior in right in payment to $1.166 billion of indebtedness under the asset-based revolving credit facility, in each case to the extent of the collateral securing such indebtedness; | ||
• the secured notes and related guarantees would have been effectively subordinated in right of payment to approximately $411 million equivalent outstanding under the senior secured European term loan facility and $181 million of other secured debt of our non-guarantor subsidiaries, which primarily represents capital leases; and | ||
• we would have had an additional $1.917 billion of unutilized capacity under the senior secured revolving credit facility and $834 million of unutilized capacity under the asset-based revolving credit facility, subject to borrowing base limitations. | ||
Guarantees | The secured notes will be fully and unconditionally guaranteed on a senior unsecured basis by HCA Holdings, Inc. and on a senior secured basis by each of our existing and future direct or indirect wholly owned domestic subsidiaries that guarantees our obligations under our senior secured credit facilities (except for certain special purpose subsidiaries that will only guarantee and pledge their assets under our asset-based revolving credit facility). | |
Ranking of the Secured Notes Guarantees | Each subsidiary guarantee of the secured notes will: | |
• rank senior in right of payment to all existing and future subordinated indebtedness of the guarantor subsidiary; | ||
• rank equally in right of payment with all existing and future senior indebtedness of the guarantor subsidiary; | ||
• be effectively senior in right of payment to the guarantees of the second lien notes to the extent of the guarantor subsidiary’s collateral securing such indebtedness and to any guarantees of unsecured indebtedness; | ||
• be effectively equal in right of payment with the guarantees of the cash flow credit facility and the first lien notes to the extent of the subsidiary guarantor’s collateral (other than certain European collateral securing the senior secured European term loan facility) securing such indebtedness; | ||
• be effectively subordinated in right of payment to the guarantees of the asset-based revolving credit facility to the extent of the guarantor subsidiary’s collateral securing such indebtedness; and | ||
• be effectively subordinated in right of payment to all existing and future indebtedness and other liabilities of our non-guarantor subsidiaries (other than indebtedness and liabilities owed to us or one of our guarantor subsidiaries). |
S-11
Table of Contents
Any subsidiary guarantee of the secured notes will be released in the event such guarantee is released under the senior secured credit facilities. | ||
As of March 31, 2011, on an as adjusted basis after giving effect to the June redemptions and the notes offered hereby and the use of proceeds therefrom, our non-guarantor subsidiaries would have accounted for approximately $3.477 billion, or 43.2%, of our total revenue, and approximately $689 million, or 43.3%, of our total Adjusted EBITDA, and approximately $9.840 billion, or 41.3%, of our total assets, and approximately $5.969 billion, or 18.9%, of our total liabilities. | ||
Security | The secured notes and related subsidiary guarantees will be secured by first-priority liens, subject to permitted liens, on certain of the assets of HCA Inc. and the subsidiary guarantors that secure our cash flow credit facility and the first lien notes on apari passubasis, including: | |
• substantially all the capital stock of any wholly owned first-tier subsidiary of HCA Inc. or of any subsidiary guarantor of the notes (but limited to 65% of the voting stock of any such wholly owned first-tier subsidiary that is a foreign subsidiary); and | ||
• substantially all tangible and intangible assets of our company and each subsidiary guarantor, other than (1) other properties that do not secure our senior secured credit facilities, (2) deposit accounts, other bank or securities accounts and cash, (3) leaseholds and motor vehicles; provided that, with respect to the portion of the collateral comprised of real property, we will have up to 60 days following the issue date of the notes to complete those actions required to perfect the first-priority lien on such collateral, (4) certain European collateral and (5) certain receivables collateral that only secures our asset-based revolving credit facility, in each case subject to exceptions, and except that the lien on properties defined as “principal properties” under our existing indenture dated as of December 16, 1993, so long as such indenture remains in effect, will be limited to securing a portion of the indebtedness under the notes, our cash flow credit facility and the first lien notes that, in the aggregate, does not exceed 10% of our consolidated net tangible assets. |
The secured notes and the related subsidiary guarantees will be secured by second-priority liens, subject to permitted liens, on certain receivables of HCA Inc. and the subsidiary guarantors that secure our asset-based revolving credit facility on a first-priority basis. See “Description of the secured notes—Security.” | ||
In the event the notes have investment grade ratings from both Moody’s Investors Service, Inc. and Standard & Poor’s. the collateral securing the secured notes and the related subsidiary guarantees will be released. In addition, to the extent the collateral is released as security for the senior secured credit facilities, it will also be released as security for the secured notes offered hereby and the |
S-12
Table of Contents
related subsidiary guarantees. See “Description of the secured notes—Security—Covenant termination and release of collateral.” |
Covenants | The indenture governing the secured notes will contain covenants limiting the Issuer’s and certain of its subsidiaries’ ability to: | |
• create liens on certain assets to secure debt; | ||
• engage in certain sale and lease-back transactions; | ||
• sell certain assets; and | ||
• consolidate, merge, sell or otherwise dispose of all or substantially all of its assets. | ||
These covenants are subject to a number of important limitations and exceptions. See “Description of the secured notes.” | ||
These covenants will cease to apply in the event that either (i) the secured notes have investment grade ratings from both Moody’s Investors Service, Inc. and Standard & Poor’s or (ii) the collateral is released as security for the senior secured credit facilities, and instead, the covenants described below under “Terms of the senior unsecured notes—Covenants” will apply to the notes. See “Description of the secured notes—Security—Covenant termination and release of collateral.” |
Issuer | HCA Inc. | |
Senior Unsecured Notes | % senior unsecured notes due 2022. | |
Maturity Date | The unsecured notes will mature on , 2022. | |
Interest Rate | Interest on the unsecured notes will be payable in cash and will accrue at a rate of % per annum. | |
Interest Payment Dates | February 15 and August 15, commencing on February 15, 2012. Interest will accrue from , 2011. | |
Ranking | The unsecured notes will be the Issuer’s senior obligations and will: | |
• rank senior in right of payment to any of its future subordinated indebtedness; | ||
• rank equally in right of payment with any of its existing and future senior indebtedness; | ||
• be effectively subordinated in right of payment to any of its existing and future secured indebtedness to the extent of the value of the collateral securing such indebtedness; and | ||
• be structurally subordinated in right of payment to all existing and future indebtedness and other liabilities of its subsidiaries. |
S-13
Table of Contents
As of March 31, 2011, on an as adjusted basis after giving effect to the June redemptions and the notes offered hereby and the use of proceeds therefrom as described under “Use of proceeds”: | ||
• the unsecured notes would have been effectively subordinated in right of payment to $17.764 billion of secured indebtedness; and | ||
• we would have had $1.917 billion of unutilized capacity under the senior secured revolving credit facility and $834 million of unutilized capacity under the asset-based revolving credit facility, after giving effect to letters of credit and borrowing base limitations, all of which would be structurally senior to the notes offered hereby if borrowed. | ||
Guarantees | The unsecured notes will be fully and unconditionally guaranteed on a senior unsecured basis by HCA Holdings, Inc. and will: | |
• rank senior in right of payment to all existing and future subordinated indebtedness of HCA Holdings, Inc.; | ||
• rank equally in right of payment with all existing and future senior indebtedness of HCA Holdings, Inc.; | ||
• be effectively subordinated in right of payment to all future secured indebtedness of HCA Holdings, Inc. to the extent of the value of the collateral securing such indebtedness; and | ||
• be effectively subordinated in right of payment to all existing and future indebtedness and other liabilities of any subsidiary of HCA Holdings, Inc. (other than HCA Inc.). | ||
The unsecured notes will not be guaranteed by any of HCA Inc.’s subsidiaries. | ||
As of March 31, 2011, on an as adjusted basis after giving effect to the June redemptions and the notes offered hereby and the use of proceeds therefrom as described under “Use of proceeds,” the unsecured notes and related guarantee would have been structurally subordinated to approximately $23.590 billion of indebtedness of HCA Inc.’s subsidiaries, $17.764 billion of which would have been secured. | ||
Covenants | The indenture governing the unsecured notes will contain covenants limiting the Issuer’s and certain of its subsidiaries’ ability to: | |
• create liens on certain assets to secure debt; | ||
• engage in certain sale and lease-back transactions; and | ||
• consolidate, merge, sell or otherwise dispose of all or substantially all of its assets. | ||
These covenants are subject to a number of important limitations and exceptions. See “Description of the unsecured notes.” |
S-14
Table of Contents
Optional Redemption | The Issuer may redeem the notes, at any time in whole or from time to time in part, at the redemption prices described in this prospectus supplement. See “Description of the secured notes—Optional redemption” and “Description of the unsecured notes—Optional redemption.” | |
Change of Control Offer | Upon the occurrence of a change of control, you will have the right, as holders of the notes, to require the Issuer to repurchase some or all of your notes at 101% of their face amount, plus accrued and unpaid interest to the repurchase date. See “Description of the secured notes—Repurchase at the option of holders—Change of control” and “Description of the unsecured notes—Repurchase at the option of holders—Change of control.” | |
The Issuer may not be able to pay you the required price for notes you present to it at the time of a change of control, because: | ||
• the Issuer may not have enough funds at that time; or | ||
• the terms of our indebtedness under the senior secured credit facilities may prevent it from making such payment. | ||
Your right to require the Issuer to repurchase the notes upon the occurrence of a change of control will cease to apply to the notes at all times during which such notes have investment grade ratings from both Moody’s Investors Service, Inc. and Standard & Poor’s. See “Description of the secured notes—Certain covenants—Covenant suspension” and “Description of the unsecured notes—Certain covenants—Covenant suspension.” | ||
No Prior Market | The notes will be new securities for which there is currently no market. Although the underwriters have informed the Issuer that they intend to make a market in the notes and they are not obligated to do so, and they may discontinue market making activities at any time without notice. Accordingly, the Issuer cannot assure you that a liquid market for the notes will develop or be maintained. | |
Use of Proceeds | We estimate that our net proceeds from this offering, after deducting underwriter discounts and commissions and estimated offering expenses, will be approximately $985 million. | |
We intend to use the net proceeds from the notes offered hereby to redeem and repurchase $900 million of our outstanding $1.578 billion 95/8%/103/8% second lien toggle notes due 2016 and for related fees and expenses. See “Use of proceeds” and “Capitalization.” | ||
Conflicts of Interest | Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory, investment banking, commercial banking and other services for us for which they received or will receive customary fees and expenses. In addition, certain of the underwritersand/or their affiliates may be holders of our 95/8%/103/8% second lien toggle notes due 2016 and, accordingly, they may receive a portion of the |
S-15
Table of Contents
net proceeds of this offering in connection with the redemption of those notes. However, none of the underwriters, nor any of their affiliates will receive net proceeds of this offering equal to or in excess of 5% of the net proceeds of this offering. | ||
Merrill Lynch, Pierce, Fenner & Smith Incorporated and/or its affiliates indirectly own in excess of 10% of our issued and outstanding common stock, and is therefore deemed to be one of our “affiliates” and have a “conflict of interest” within the meaning of the provisions of Rule 5121 of the Financial Industry Regulatory Authority, Inc. Conduct Rules (“FINRA Rule 5121”). Accordingly, this offering is being conducted in accordance with FINRA Rule 5121 regarding the underwriting of securities. FINRA Rule 5121 requires that a “qualified independent underwriter” as defined by the FINRA rules participate in the preparation of the registration statement of which this prospectus forms a part and perform its usual standard of due diligence with respect thereto. Barclays Capital Inc. has agreed to serve as the qualified independent underwriter for the offering. See “Underwriting (conflicts of interest).” |
S-16
Table of Contents
Three months ended | ||||||||||||||||||||
Years ended December 31, | March 31, | |||||||||||||||||||
(dollars in millions) | 2010 | 2009 | 2008 | 2011 | 2010 | |||||||||||||||
(unaudited) | ||||||||||||||||||||
Income Statement Data: | ||||||||||||||||||||
Revenues | $ | 30,683 | $ | 30,052 | $ | 28,374 | $ | 8,055 | $ | 7,544 | ||||||||||
Salaries and benefits | 12,484 | 11,958 | 11,440 | 3,295 | 3,072 | |||||||||||||||
Supplies | 4,961 | 4,868 | 4,620 | 1,275 | 1,200 | |||||||||||||||
Other operating expenses | 5,004 | 4,724 | 4,554 | 1,322 | 1,202 | |||||||||||||||
Provision for doubtful accounts | 2,648 | 3,276 | 3,409 | 649 | 564 | |||||||||||||||
Equity in earnings of affiliates | (282 | ) | (246 | ) | (223 | ) | (76 | ) | (68 | ) | ||||||||||
Depreciation and amortization | 1,421 | 1,425 | 1,416 | 358 | 355 | |||||||||||||||
Interest expense | 2,097 | 1,987 | 2,021 | 533 | 516 | |||||||||||||||
Losses (gains) on sales of facilities | (4 | ) | 15 | (97 | ) | 1 | – | |||||||||||||
Impairments of long-lived assets | 123 | 43 | 64 | – | 18 | |||||||||||||||
Termination of management agreement | – | – | – | 181 | – | |||||||||||||||
28,452 | 28,050 | 27,204 | 7,538 | 6,859 | ||||||||||||||||
Income before income taxes | 2,231 | 2,002 | 1,170 | 517 | 685 | |||||||||||||||
Provision for income taxes | 658 | 627 | 268 | 183 | 209 | |||||||||||||||
Net income | 1,573 | 1,375 | 902 | 334 | 476 | |||||||||||||||
Net income attributable to noncontrolling interests | 366 | 321 | 229 | 94 | 88 | |||||||||||||||
Net income attributable to HCA Holdings, Inc. | $ | 1,207 | $ | 1,054 | $ | 673 | $ | 240 | $ | 388 | ||||||||||
S-17
Table of Contents
Three months ended | ||||||||||||||||||||
Years ended December 31, | March 31, | |||||||||||||||||||
(dollars in millions) | 2010 | 2009 | 2008 | 2011 | 2010 | |||||||||||||||
(unaudited) | ||||||||||||||||||||
Statement of Cash Flows Data: | ||||||||||||||||||||
Cash flows provided by operating activities | $ | 3,085 | $ | 2,747 | $ | 1,990 | $ | 918 | $ | 859 | ||||||||||
Cash flows used in investing activities | (1,039 | ) | (1,035 | ) | (1,467 | ) | (273 | ) | (181 | ) | ||||||||||
Cash flows used in financing activities | (1,947 | ) | (1,865 | ) | (451 | ) | (503 | ) | (602 | ) | ||||||||||
Other Financial Data: | ||||||||||||||||||||
EBITDA(1) | $ | 5,383 | $ | 5,093 | $ | 4,378 | $ | 1,314 | $ | 1,468 | ||||||||||
Adjusted EBITDA(1) | 5,868 | 5,472 | 4,574 | 1,590 | 1,574 | |||||||||||||||
Capital expenditures | 1,325 | 1,317 | 1,600 | 329 | 214 | |||||||||||||||
Operating Data:(2) | ||||||||||||||||||||
Number of hospitals at end of period(3) | 156 | 155 | 158 | 156 | 154 | |||||||||||||||
Number of freestanding outpatient surgical centers at end of period(4) | 97 | 97 | 97 | 98 | 98 | |||||||||||||||
Number of licensed beds at end of period(5) | 38,827 | 38,839 | 38,504 | 39,075 | 38,719 | |||||||||||||||
Weighted average licensed beds(6) | 38,655 | 38,825 | 38,422 | 39,061 | 38,687 | |||||||||||||||
Admissions(7) | 1,554,400 | 1,556,500 | 1,541,800 | 406,900 | 398,900 | |||||||||||||||
Equivalent admissions(8) | 2,468,400 | 2,439,000 | 2,363,600 | 638,400 | 615,500 | |||||||||||||||
Average length of stay (days)(9) | 4.8 | 4.8 | 4.9 | 4.9 | 4.9 | |||||||||||||||
Average daily census(10) | 20,523 | 20,650 | 20,795 | 22,002 | 21,696 | |||||||||||||||
Occupancy(11) | 53 | % | 53 | % | 54 | % | 56 | % | 56 | % | ||||||||||
Emergency room visits(12) | 5,706,200 | 5,593,500 | 5,246,400 | 1,527,600 | 1,367,100 | |||||||||||||||
Outpatient surgeries(13) | 783,600 | 794,600 | 797,400 | 193,000 | 190,700 | |||||||||||||||
Inpatient surgeries(14) | 487,100 | 494,500 | 493,100 | 119,700 | 122,500 | |||||||||||||||
Days revenues in accounts receivable(15) | 46 | 45 | 49 | 45 | 46 | |||||||||||||||
Gross patient revenues(16) | $ | 125,640 | $ | 115,682 | $ | 102,843 | $ | 34,764 | $ | 31,054 | ||||||||||
Outpatient revenues as a percentage of patient revenues(17) | 38 | % | 38 | % | 37 | % | 38 | % | 36 | % | ||||||||||
Balance Sheet Data: | ||||||||||||||||||||
Working capital(18) | $ | 2,650 | $ | 2,264 | $ | 2,391 | $ | 2,719 | $ | 2,167 | ||||||||||
Property, plant and equipment, net | 11,352 | 11,427 | 11,529 | 11,347 | 11,252 | |||||||||||||||
Cash and cash equivalents | 411 | 312 | 465 | 553 | 388 | |||||||||||||||
Total assets | 23,852 | 24,131 | 24,280 | 23,809 | 24,091 | |||||||||||||||
Total debt | 28,225 | 25,670 | 26,989 | 25,366 | 26,855 | |||||||||||||||
Equity securities with contingent redemption rights | 141 | 147 | 155 | – | 144 | |||||||||||||||
Stockholders’ deficit attributable to HCA Holdings, Inc. | (11,926 | ) | (8,986 | ) | (10,255 | ) | (8,930 | ) | (10,313 | ) | ||||||||||
Noncontrolling interests | 1,132 | 1,008 | 995 | 1,142 | 1,015 | |||||||||||||||
Total stockholders’ deficit | (10,794 | ) | (7,978 | ) | (9,260 | ) | (7,788 | ) | (9,298 | ) | ||||||||||
(1) | EBITDA, a measure used by management to evaluate operating performance, is defined as net income attributable to HCA Holdings, Inc. plus (i) provision for income taxes, (ii) interest expense and (iii) depreciation and amortization. EBITDA is not a recognized term under GAAP and does not purport to be an alternative to net income as a measure of operating performance or to cash flows from operating activities as a measure of liquidity. Additionally, EBITDA is not intended to be a |
S-18
Table of Contents
measure of free cash flow available for management’s discretionary use, as it does not consider certain cash requirements such as interest payments, tax payments and other debt service requirements. Management believes EBITDA is helpful to investors and our management in highlighting trends because EBITDA excludes the results of decisions outside the control of operating management and that can differ significantly from company to company depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which companies operate and capital investments. Management compensates for the limitations of using non-GAAP financial measures by using them to supplement GAAP results to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. Because not all companies use identical calculations, our presentation of EBITDA may not be comparable to similarly titled measures of other companies. | ||
Adjusted EBITDA is defined as EBITDA, adjusted to exclude net income attributable to noncontrolling interests, losses (gains) on sales of facilities, impairments of long-lived assets and termination of management agreement. We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as the primary measure to review and assess operating performance of its hospital facilities and their management teams. Adjusted EBITDA target amounts are the performance measures utilized in our annual incentive compensation programs and are vesting conditions for a portion of our stock option grants. Management and investors review both the overall performance (GAAP net income attributable to HCA Holdings, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that losses (gains) on sales of facilities and impairment of long-lived assets will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies. Adjusted EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States, and should not be considered an alternative to net income attributable to HCA Holdings, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies. There may be additional adjustments to Adjusted EBITDA under our agreements governing our material debt obligations, including the notes offered hereby. | ||
EBITDA and Adjusted EBITDA are calculated as follows: |
Three months ended | ||||||||||||||||||||
Years ended December 31, | March 31, | |||||||||||||||||||
(dollars in millions) | 2010 | 2009 | 2008 | 2011 | 2010 | |||||||||||||||
(unaudited) | ||||||||||||||||||||
Net income attributable to HCA Holdings, Inc. | $ | 1,207 | $ | 1,054 | $ | 673 | $ | 240 | $ | 388 | ||||||||||
Provision for income taxes | 658 | 627 | 268 | 183 | 209 | |||||||||||||||
Interest expense | 2,097 | 1,987 | 2,021 | 533 | 516 | |||||||||||||||
Depreciation and amortization | 1,421 | 1,425 | 1,416 | 358 | 355 | |||||||||||||||
EBITDA | 5,383 | 5,093 | 4,378 | 1,314 | 1,468 | |||||||||||||||
Net income attributable to noncontrolling interests(i) | 366 | 321 | 229 | 94 | 88 | |||||||||||||||
Losses (gains) on sales of facilities(ii) | (4 | ) | 15 | (97 | ) | 1 | – | |||||||||||||
Impairments of long-lived assets(iii) | 123 | 43 | 64 | – | 18 | |||||||||||||||
Termination of management agreement(iv) | – | – | – | 181 | – | |||||||||||||||
Adjusted EBITDA | $ | 5,868 | $ | 5,472 | $ | 4,574 | $ | 1,590 | $ | 1,574 | ||||||||||
(i) | Represents the add-back of net income attributable to noncontrolling interests. | |
(ii) | Represents the elimination of losses (gains) on sales of facilities. | |
(iii) | Represents the add-back of impairments of long-lived assets. | |
(iv) | Represents the add-back of termination of management agreement. |
(2) | The operating data set forth in this table includes only those facilities that are consolidated for financial reporting purposes. | |
(3) | Excludes facilities that are not consolidated (accounted for using the equity method) for financial reporting purposes. | |
(4) | Excludes facilities that are not consolidated (accounted for using the equity method) for financial reporting purposes. | |
(5) | Licensed beds are those beds for which a facility has been granted approval to operate from the applicable state licensing agency. | |
(6) | Represents the average number of licensed beds, weighted based on periods owned. | |
(7) | Represents the total number of patients admitted to our hospitals and is used by management and certain investors as a general measure of inpatient volume. | |
(8) | Equivalent admissions are used by management and certain investors as a general measure of combined inpatient and outpatient volume. Equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross |
S-19
Table of Contents
inpatient revenues and gross outpatient revenues and then dividing the resulting amount by gross inpatient revenues. The equivalent admissions computation “equates” outpatient revenues to the volume measure (admissions) used to measure inpatient volume, resulting in a general measure of combined inpatient and outpatient volume. | ||
(9) | Represents the average number of days admitted patients stay in our hospitals. | |
(10) | Represents the average number of patients in our hospital beds each day. | |
(11) | Represents the percentage of hospital licensed beds occupied by patients. Both average daily census and occupancy rate provide measures of the utilization of inpatient rooms. | |
(12) | Represents the number of patients treated in our emergency rooms. | |
(13) | Represents the number of surgeries performed on patients who were not admitted to our hospitals. Pain management and endoscopy procedures are not included in outpatient surgeries. | |
(14) | Represents the number of surgeries performed on patients who have been admitted to our hospitals. Pain management and endoscopy procedures are not included in inpatient surgeries. | |
(15) | Revenues per day is calculated by dividing the revenues for the period by the days in the period. Days revenues in accounts receivable is then calculated as accounts receivable, net of the allowance for doubtful accounts, at the end of the period divided by revenues per day. | |
(16) | Gross patient revenues are based upon our standard charge listing. Gross charges/revenues typically do not reflect what our hospital facilities are paid. Gross charges/revenues are reduced by contractual adjustments, discounts and charity care to determine reported revenues. | |
(17) | Represents the percentage of patient revenues related to patients who are not admitted to our hospitals. | |
(18) | We define working capital as current assets minus current liabilities. |
S-20
Table of Contents
• | increasing our vulnerability to downturns or adverse changes in general economic, industry or competitive conditions and adverse changes in government regulations; |
• | requiring a substantial portion of cash flow from operations to be dedicated to the payment of principal and interest on our indebtedness, therefore reducing our ability to use our cash flow to fund our operations, capital expenditures and future business opportunities; |
• | exposing us to the risk of increased interest rates as certain of our unhedged borrowings are at variable rates of interest; |
• | limiting our ability to make strategic acquisitions or causing us to make nonstrategic divestitures; |
• | limiting our ability to obtain additional financing for working capital, capital expenditures, product or service line development, debt service requirements, acquisitions and general corporate or other purposes; and |
• | limiting our ability to adjust to changing market conditions and placing us at a competitive disadvantage compared to our competitors who are less highly leveraged. |
S-21
Table of Contents
S-22
Table of Contents
• | incur additional indebtedness or issue certain preferred shares; |
• | pay dividends on, repurchase or make distributions in respect of our capital stock or make other restricted payments; |
• | make certain investments; |
• | sell or transfer assets; |
• | create liens; |
• | consolidate, merge, sell or otherwise dispose of all or substantially all of our assets; and |
• | enter into certain transactions with our affiliates. |
S-23
Table of Contents
• | we or any of the guarantors, as applicable, were insolvent or rendered insolvent by reason of the issuance of the notes or the incurrence of the guarantees; |
• | the issuance of the notes or the incurrence of the guarantees left us or any of the guarantors, as applicable, with an unreasonably small amount of capital to carry on the business; |
• | we or any of the guarantors intended to, or believed that we or such guarantor would, incur debts beyond our or such guarantor’s ability to pay as they mature; or |
• | we were or any of the guarantors was a defendant in an action for money damages, or had a judgment for money damages docketed against us or such guarantor if, in either case, after final judgment, the judgment was unsatisfied. |
• | the sum of its debts, including contingent liabilities, was greater than the fair saleable value of all its assets; |
• | the present fair saleable value of its assets was less than the amount that would be required to pay its probable liability on its existing debts, including contingent liabilities, as they become absolute and mature; or |
• | it could not pay its debts as they become due. |
S-24
Table of Contents
S-25
Table of Contents
S-26
Table of Contents
S-27
Table of Contents
S-28
Table of Contents
S-29
Table of Contents
S-30
Table of Contents
• | a sale, transfer or other disposal of such collateral in a transaction not prohibited under the indenture; |
• | with respect to collateral held by a guarantor, upon the release of such guarantor from its guarantee; |
• | with respect to collateral that is capital stock, upon the dissolution of the issuer of such capital stock in accordance with the indenture; |
• | with respect to any receivables collateral in which the secured notes have a second-priority lien, upon any release by the lenders under our asset-based revolving credit facility of their first-priority security interest in such collateral; provided that, if the release occurs in connection with a foreclosure or exercise of remedies by the collateral agent for the lenders under our asset-based revolving credit facility, the lien on that collateral will be automatically released but any proceeds thereof not used to repay the obligations under our asset-based revolving credit facility will be subject to a lien in favor of the collateral agent for the secured noteholders and our cash flow credit facility; |
• | with respect to the collateral upon which the secured notes have a first-priority lien, upon any release by the lenders under the cash flow credit facility (including in connection with a foreclosure or exercise of remedies with respect to that collateral directed by the authorized representative of the lenders under our cash flow credit facility during any period that such authorized representative controls actions with respect to the collateral pursuant to the first lien intercreditor agreement); and |
• | the collateral securing the secured notes will be released once the secured notes achieve investment grade ratings from Moody’s Investors Service, Inc. and Standard & Poor’s Rating Services, and at such time no default or event of default has occurred and is continuing. |
S-31
Table of Contents
S-32
Table of Contents
S-33
Table of Contents
S-34
Table of Contents
S-35
Table of Contents
S-36
Table of Contents
• | as adjusted to give effect to our redemption in June 2011 of all $1.000 billion aggregate principal amount of 91/8% second lien notes due 2014 and $108.5 million aggregate principal amount of 97/8% second lien notes due 2017 (the “June redemptions”); and |
• | as further adjusted to give effect to this offering and the use of proceeds therefrom to redeem $900 million of the $1.578 billion aggregate principal amount of 95/8%/103/8% second lien toggle notes due 2016. |
As of March 31, 2011 | ||||||||
As adjusted | As further | |||||||
for the June | adjusted for this | |||||||
(dollars in millions) | redemptions | offering | ||||||
(unaudited) | ||||||||
Cash and cash equivalents | $ | 553 | $ | 553 | ||||
Senior secured credit facilities(1) | $ | 8,720 | $ | 8,720 | ||||
Existing first lien notes(2) | 4,076 | 4,076 | ||||||
Secured notes offered hereby(3) | – | 500 | ||||||
Other secured indebtedness(4) | 314 | 314 | ||||||
Existing second lien notes(5) | 4,974 | 4,074 | ||||||
Total senior secured indebtedness | 18,084 | 17,684 | ||||||
Existing unsecured indebtedness(6) | 7,342 | 7,342 | ||||||
Senior unsecured notes offered hereby(3) | – | 500 | ||||||
Total debt | 25,426 | 25,526 | ||||||
Stockholders’ deficit attributable to HCA Holdings, Inc. | (8,977 | ) | (9,024 | ) | ||||
Noncontrolling interests | 1,142 | 1,142 | ||||||
Total stockholders’ deficit | (7,835 | ) | (7,882 | ) | ||||
Total capitalization | $ | 17,591 | $ | 17,644 | ||||
(1) | Consists of (i) a $2.000 billion asset-based revolving credit facility maturing on November 16, 2012 (the “asset-based revolving credit facility”) ($1.166 billion outstanding at March 31, 2011, as adjusted to give effect to the June redemptions); (ii) a $2.000 billion senior secured revolving credit facility maturing on November 17, 2015 (the “senior secured revolving credit facility”) (none outstanding at March 31, 2011, without giving effect to outstanding letters of credit); (iii) a $487 million senior secured term loanA-1 facility maturing on November 17, 2012; (iv) a $594 million senior secured term loanA-2 facility maturing on May 2, 2016; (v) a $1.689 billion senior secured term loan B-1 facility maturing on November 17, 2013; (vi) a $2.000 billion senior secured term loan B-2 facility maturing on March 31, 2017; (vii) a $2.373 billion senior secured term loan B-3 facility maturing on May 1, 2018; and (viii) a €291 million, or $411 million-equivalent, senior secured European term loan facility maturing on November 17, 2013. We refer to the facilities described under (ii) through (viii) above, collectively, as the “cash flow credit facility” and, together with the asset-based revolving credit facility, the “senior secured credit facilities.” Does not give effect to amounts that may be drawn under the revolving credit facility to fund our acquisition of HCA-HealthONE®, LLC, if consummated. See “Summary—Recent developments.” | |
(2) | Consists of (i) $1.500 billion aggregate principal amount of 81/2% first lien notes due 2019 that HCA Inc. issued in April 2009 (the “April 2009 first lien notes”); (ii) $1.250 billion aggregate principal amount of 77/8% first lien notes due 2020 that HCA Inc. issued in August 2009 (the “August 2009 first lien notes”), (iii) $1.400 billion aggregate principal amount of 71/4% first lien notes due 2020 that HCA Inc. issued in March 2010 (the “March 2010 first lien notes” and, collectively with the April |
S-37
Table of Contents
2009 first lien notes and the August 2009 first lien notes, the “first lien notes”) and (iv) $74 million of unamortized debt discounts that reduce the existing indebtedness. | ||
(3) | The respective aggregate principal amounts of secured notes and unsecured notes presented in this table are for indicative purposes only. | |
(4) | Consists of capital leases and other secured debt with a weighted average interest rate of 7.12%. | |
(5) | Consists of (i) $3.200 billion of 91/4% second lien notes due 2016, (ii) $1.578 billion of 95/8%/103/8% second lien toggle notes due 2016 ($900 million of which are intended to be redeemed with the net proceeds from this offering), (iii) $310 million aggregate principal amount of 97/8% second lien notes due 2017 ($108.5 million of which were redeemed in the June redemptions) and (iv) $6 million of unamortized debt discounts that reduce the existing indebtedness. We refer to the notes issued in (i) through (iii) above, collectively as the “second lien notes” and, together with the first lien notes, the “existing secured notes.” | |
(6) | Consists of HCA Inc.’s (i) an aggregate principal amount of $246 million medium-term notes with maturities ranging from 2014 to 2025 and a weighted average interest rate of 8.28%; (ii) an aggregate principal amount of $886 million debentures with maturities ranging from 2015 to 2095 and a weighted average interest rate of 7.55%; (iii) an aggregate principal amount of $4.694 billion senior notes with maturities ranging from 2012 to 2033 and a weighted average interest rate of 6.54%; and (iv) $9 million of unamortized debt discounts that reduce the existing indebtedness. Existing unsecured indebtedness also includes HCA Holdings, Inc.’s $1.525 billion aggregate principal amount of 73/4% senior notes due 2010. For more information regarding our unsecured and other indebtedness, see “Description of other indebtedness.” |
S-38
Table of Contents
Condensed Consolidated Income Statements
For the Quarters Ended June 30, 2011 and 2010
(Dollars in millions, except per share amounts)
2011 | 2010 | |||||||||||||||
Amount | Ratio | Amount | Ratio | |||||||||||||
Revenues | $ | 8,063 | 100.0 | % | $ | 7,756 | 100.0 | % | ||||||||
Salaries and benefits | 3,320 | 41.2 | 3,076 | 39.6 | ||||||||||||
Supplies | 1,295 | 16.1 | 1,251 | 16.1 | ||||||||||||
Other operating expenses | 1,326 | 16.4 | 1,226 | 15.9 | ||||||||||||
Provision for doubtful accounts | 775 | 9.6 | 788 | 10.2 | ||||||||||||
Equity in earnings of affiliates | (73 | ) | (0.9 | ) | (75 | ) | (1.0 | ) | ||||||||
Depreciation and amortization | 358 | 4.5 | 355 | 4.6 | ||||||||||||
Interest expense | 520 | 6.4 | 530 | 6.8 | ||||||||||||
Impairments of long-lived assets | – | – | 91 | 1.2 | ||||||||||||
Loss on retirement of debt | 75 | 0.9 | – | – | ||||||||||||
7,596 | 94.2 | 7,242 | 93.4 | |||||||||||||
Income before income taxes | 467 | 5.8 | 514 | 6.6 | ||||||||||||
Provision for income taxes | 147 | 1.8 | 136 | 1.7 | ||||||||||||
Net income | 320 | 4.0 | 378 | 4.9 | ||||||||||||
Net income attributable to noncontrolling interests | 91 | 1.2 | 85 | 1.1 | ||||||||||||
Net income attributable to HCA Holdings, Inc. | $ | 229 | 2.8 | $ | 293 | 3.8 | ||||||||||
Diluted earnings per share | $ | 0.43 | $ | 0.67 | ||||||||||||
Shares used in computing diluted earnings per share (000) | 538,557 | 437,104 |
S-39
Table of Contents
Condensed Consolidated Income Statements
For the Six Months Ended June 30, 2011 and 2010
(Dollars in millions, except per share amounts)
2011 | 2010 | |||||||||||||||
Amount | Ratio | Amount | Ratio | |||||||||||||
Revenues | $ | 16,118 | 100.0 | % | $ | 15,300 | 100.0 | % | ||||||||
Salaries and benefits | 6,615 | 41.0 | 6,148 | 40.2 | ||||||||||||
Supplies | 2,570 | 15.9 | 2,451 | 16.0 | ||||||||||||
Other operating expenses | 2,648 | 16.5 | 2,428 | 15.9 | ||||||||||||
Provision for doubtful accounts | 1,424 | 8.8 | 1,352 | 8.8 | ||||||||||||
Equity in earnings of affiliates | (149 | ) | (0.9 | ) | (143 | ) | (0.9 | ) | ||||||||
Depreciation and amortization | 716 | 4.5 | 710 | 4.7 | ||||||||||||
Interest expense | 1,053 | 6.5 | 1,046 | 6.8 | ||||||||||||
Losses on sales of facilities | 1 | – | – | – | ||||||||||||
Impairments of long-lived assets | – | – | 109 | 0.7 | ||||||||||||
Loss on retirement of debt | 75 | 0.5 | – | – | ||||||||||||
Termination of management agreement | 181 | 1.1 | – | – | ||||||||||||
15,134 | 93.9 | 14,101 | 92.2 | |||||||||||||
Income before income taxes | 984 | 6.1 | 1,199 | 7.8 | ||||||||||||
Provision for income taxes | 330 | 2.0 | 345 | 2.2 | ||||||||||||
Net income | 654 | 4.1 | 854 | 5.6 | ||||||||||||
Net income attributable to noncontrolling interests | 185 | 1.2 | 173 | 1.1 | ||||||||||||
Net income attributable to HCA Holdings, Inc. | $ | 469 | 2.9 | $ | 681 | 4.5 | ||||||||||
Diluted earnings per share | $ | 0.94 | $ | 1.56 | ||||||||||||
Shares used in computing diluted earnings per share (000) | 500,463 | 436,392 |
S-40
Table of Contents
Condensed Consolidated Balance Sheets
(Dollars in millions)
June 30, | March 31, | December 31, | ||||||||||
2011 | 2011 | 2010 | ||||||||||
ASSETS | ||||||||||||
Current assets: | ||||||||||||
Cash and cash equivalents | $ | 539 | $ | 553 | $ | 411 | ||||||
Accounts receivable, net | 3,946 | 4,060 | 3,832 | |||||||||
Inventories | 887 | 881 | 897 | |||||||||
Deferred income taxes | 894 | 916 | 931 | |||||||||
Other | 625 | 576 | 848 | |||||||||
Total current assets | 6,891 | 6,986 | 6,919 | |||||||||
Property and equipment, at cost | 26,338 | 25,855 | 25,641 | |||||||||
Accumulated depreciation | (14,754 | ) | (14,508 | ) | (14,289 | ) | ||||||
11,584 | 11,347 | 11,352 | ||||||||||
Investments of insurance subsidiary | 515 | 590 | 642 | |||||||||
Investments in and advances to affiliates | 843 | 852 | 869 | |||||||||
Goodwill | 2,719 | 2,705 | 2,693 | |||||||||
Deferred loan costs | 332 | 354 | 374 | |||||||||
Other | 993 | 975 | 1,003 | |||||||||
$ | 23,877 | $ | 23,809 | $ | 23,852 | |||||||
LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||
Current liabilities: | ||||||||||||
Accounts payable | $ | 1,297 | $ | 1,348 | $ | 1,537 | ||||||
Accrued salaries | 1,009 | 975 | 895 | |||||||||
Other accrued expenses | 1,283 | 1,398 | 1,245 | |||||||||
Long-term debt due within one year | 689 | 546 | 592 | |||||||||
Total current liabilities | 4,278 | 4,267 | 4,269 | |||||||||
Long-term debt | 24,631 | 24,820 | 27,633 | |||||||||
Professional liability risks | 987 | 1,003 | 995 | |||||||||
Income taxes and other liabilities | 1,515 | 1,507 | 1,608 | |||||||||
Total liabilities | 31,411 | 31,597 | 34,505 | |||||||||
Equity securities with contingent redemption rights | – | – | 141 | |||||||||
EQUITY (DEFICIT) | ||||||||||||
HCA Holdings, Inc. stockholders’ deficit | (8,681 | ) | (8,930 | ) | (11,926 | ) | ||||||
Noncontrolling interests | 1,147 | 1,142 | 1,132 | |||||||||
Total deficit | (7,534 | ) | (7,788 | ) | (10,794 | ) | ||||||
$ | 23,877 | $ | 23,809 | $ | 23,852 | |||||||
S-41
Table of Contents
Condensed Consolidated Statements of Cash Flows
For the Six Months Ended June 30, 2011 and 2010
(Dollars in millions)
2011 | 2010 | |||||||
Cash flows from operating activities: | ||||||||
Net income | $ | 654 | $ | 854 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Changes in operating assets and liabilities | (1,576 | ) | (1,698 | ) | ||||
Provision for doubtful accounts | 1,424 | 1,352 | ||||||
Depreciation and amortization | 716 | 710 | ||||||
Income taxes | 317 | (111 | ) | |||||
Losses on sales of facilities | 1 | – | ||||||
Impairments of long-lived assets | – | 109 | ||||||
Loss on retirement of debt | 75 | – | ||||||
Amortization of deferred loan costs | 39 | 40 | ||||||
Share-based compensation | 16 | 16 | ||||||
Other | – | 23 | ||||||
Net cash provided by operating activities | 1,666 | 1,295 | ||||||
Cash flows from investing activities: | ||||||||
Purchase of property and equipment | (776 | ) | (536 | ) | ||||
Acquisition of hospitals and health care entities | (168 | ) | (31 | ) | ||||
Disposition of hospitals and health care entities | 54 | 25 | ||||||
Change in investments | 76 | 502 | ||||||
Other | 2 | (11 | ) | |||||
Net cash used in investing activities | (812 | ) | (51 | ) | ||||
Cash flows from financing activities: | ||||||||
Issuance of long-term debt | – | 1,387 | ||||||
Net change in revolving credit facilities | (1,524 | ) | 1,329 | |||||
Repayment of long-term debt | (1,508 | ) | (1,529 | ) | ||||
Distributions to noncontrolling interests | (185 | ) | (176 | ) | ||||
Distributions to stockholders | (30 | ) | (2,251 | ) | ||||
Payment of debt issuance costs | (12 | ) | (25 | ) | ||||
Issuance of common stock | 2,506 | – | ||||||
Income tax benefits | 49 | 56 | ||||||
Other | (22 | ) | 3 | |||||
Net cash used in financing activities | (726 | ) | (1,206 | ) | ||||
Change in cash and cash equivalents | 128 | 38 | ||||||
Cash and cash equivalents at beginning of period | 411 | 312 | ||||||
Cash and cash equivalents at end of period | $ | 539 | $ | 350 | ||||
Interest payments | $ | 1,043 | $ | 973 | ||||
Income tax (refunds) payments, net | $ | (36 | ) | $ | 400 |
S-42
Table of Contents
Operating Statistics
Second Quarter | For the Six Months Ended June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Consolidating Hospitals: | ||||||||||||||||
Number of Hospitals | 157 | 154 | 157 | 154 | ||||||||||||
Weighted Average Licensed Beds | 39,356 | 38,607 | 39,209 | 38,647 | ||||||||||||
Licensed Beds at End of Period | 39,472 | 38,636 | 39,472 | 38,636 | ||||||||||||
Reported: | ||||||||||||||||
Admissions | 397,500 | 385,200 | 804,400 | 784,100 | ||||||||||||
% Change | 3.2 | % | 2.6 | % | ||||||||||||
Equivalent Admissions | 638,900 | 617,900 | 1,277,300 | 1,233,400 | ||||||||||||
% Change | 3.4 | % | 3.6 | % | ||||||||||||
Revenue per Equivalent Admission | $ | 12,620 | $ | 12,553 | $ | 12,618 | $ | 12,405 | ||||||||
% Change | 0.5 | % | 1.7 | % | ||||||||||||
Inpatient Revenue per Admission | $ | 12,105 | $ | 12,211 | $ | 12,101 | $ | 12,017 | ||||||||
% Change | −0.9 | % | 0.7 | % | ||||||||||||
Patient Days | 1,889,600 | 1,858,100 | 3,869,800 | 3,810,700 | ||||||||||||
Equivalent Patient Days | 3,038,300 | 2,981,300 | 6,145,200 | 5,994,200 | ||||||||||||
Inpatient Surgery Cases | 120,200 | 121,800 | 239,900 | 244,300 | ||||||||||||
% Change | −1.3 | % | −1.8 | % | ||||||||||||
Outpatient Surgery Cases | 199,100 | 198,600 | 392,100 | 389,300 | ||||||||||||
% Change | 0.3 | % | 0.7 | % | ||||||||||||
Emergency Room Visits | 1,512,000 | 1,436,200 | 3,039,600 | 2,803,300 | ||||||||||||
% Change | 5.3 | % | 8.4 | % | ||||||||||||
Outpatient Revenues as a Percentage of Patient Revenues | 39.0 | % | 38.2 | % | 38.4 | % | 37.3 | % | ||||||||
Average Length of Stay | 4.8 | 4.8 | 4.8 | 4.9 | ||||||||||||
Occupancy | 52.8 | % | 52.9 | % | 54.5 | % | 54.5 | % | ||||||||
Equivalent Occupancy | 84.8 | % | 84.9 | % | 86.5 | % | 85.7 | % | ||||||||
Same Facility: | ||||||||||||||||
Admissions | 391,800 | 384,800 | 795,800 | 782,300 | ||||||||||||
% Change | 1.8 | % | 1.7 | % | ||||||||||||
Equivalent Admissions | 628,900 | 617,300 | 1,262,200 | 1,229,800 | ||||||||||||
% Change | 1.9 | % | 2.6 | % | ||||||||||||
Revenue per Equivalent Admission | $ | 12,573 | $ | 12,515 | $ | 12,564 | $ | 12,383 | ||||||||
% Change | 0.5 | % | 1.5 | % | ||||||||||||
Inpatient Revenue per Admission | $ | 12,094 | $ | 12,224 | $ | 12,104 | $ | 12,029 | ||||||||
% Change | −1.1 | % | 0.6 | % | ||||||||||||
Inpatient Surgery Cases | 119,200 | 121,100 | 237,800 | 242,600 | ||||||||||||
% Change | −1.5 | % | −2.0 | % | ||||||||||||
Outpatient Surgery Cases | 195,800 | 197,000 | 386,500 | 386,000 | ||||||||||||
% Change | −0.6 | % | 0.1 | % | ||||||||||||
Emergency Room Visits | 1,494,800 | 1,430,900 | 3,011,500 | 2,793,200 | ||||||||||||
% Change | 4.5 | % | 7.8 | % | ||||||||||||
Number of Consolidating and Nonconsolidating | ||||||||||||||||
(Equity Joint Ventures) Hospitals: | ||||||||||||||||
Consolidating | 157 | 154 | 157 | 154 | ||||||||||||
Nonconsolidating (Equity Joint Ventures) | 7 | 8 | 7 | 8 | ||||||||||||
Total Number of Hospitals | 164 | 162 | 164 | 162 | ||||||||||||
S-43
Table of Contents
S-44
Table of Contents
S-45
Table of Contents
Supplemental Non-GAAP Disclosures
Operating Results Summary
(Dollars in millions, except per share amounts)
For the Six Months Ended | ||||||||||||||||
Second Quarter | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Revenues | $ | 8,063 | $ | 7,756 | $ | 16,118 | $ | 15,300 | ||||||||
Net income attributable to HCA Holdings, Inc. | $ | 229 | $ | 293 | $ | 469 | $ | 681 | ||||||||
Losses on sales of facilities (net of tax) | 1 | – | 3 | – | ||||||||||||
Impairments of long-lived assets (net of tax) | − | 57 | – | 69 | ||||||||||||
Loss on retirement of debt (net of tax) | 47 | – | 47 | – | ||||||||||||
Termination of management agreement (net of tax) | − | – | 149 | – | ||||||||||||
Net income attributable to HCA Holdings, Inc., excluding losses on sales of facilities, impairments of long-lived assets, loss on retirement of debt and termination of management agreement(a) | 277 | 350 | 668 | 750 | ||||||||||||
Depreciation and amortization | 358 | 355 | 716 | 710 | ||||||||||||
Interest expense | 520 | 530 | 1,053 | 1,046 | ||||||||||||
Provision for income taxes | 174 | 170 | 388 | 385 | ||||||||||||
Net income attributable to noncontrolling interests | 91 | 85 | 185 | 173 | ||||||||||||
Adjusted EBITDA(a) | $ | 1,420 | $ | 1,490 | $ | 3,010 | $ | 3,064 | ||||||||
Diluted earnings per share: | ||||||||||||||||
Net income attributable to HCA Holdings, Inc. | $ | 0.43 | $ | 0.67 | $ | 0.94 | $ | 1.56 | ||||||||
Losses on sales of facilities | − | – | 0.01 | – | ||||||||||||
Impairments of long-lived assets | − | 0.13 | – | 0.16 | ||||||||||||
Loss on retirement of debt | 0.08 | – | 0.09 | – | ||||||||||||
Termination of management agreement | − | – | 0.30 | – | ||||||||||||
Net income attributable to HCA Holdings, Inc., excluding losses on sales of facilities, impairments of long-lived assets, loss on retirement of debt and termination of management agreement(a) | $ | 0.51 | $ | 0.80 | $ | 1.34 | $ | 1.72 | ||||||||
Shares used in computing diluted earnings per share (000) | 538,557 | 437,104 | 500,463 | 436,392 |
(a) | Net income attributable to HCA Holdings, Inc., excluding losses on sales of facilities, impairments of long-lived assets, loss on retirement of debt and termination of management agreement and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). We believe net income attributable to HCA Holdings, Inc., excluding losses on sales of facilities, impairments of long-lived assets, loss on retirement of debt and termination of management agreement and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Holdings, Inc., excluding losses on sales of facilities, impairments of long-lived assets, loss on retirement of debt and termination of management agreement and Adjusted EBITDA as the primary measures to review and assess operating performance of its hospital facilities and their management teams. | |
Management and investors review both the overall performance (including net income attributable to HCA Holdings, Inc., excluding losses on sales of facilities, impairments of long-lived assets, loss on retirement of debt and termination of management agreement and GAAP net income attributable to HCA Holdings, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that losses on sales of facilities, impairments of long-lived assets and loss on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies. | ||
Net income attributable to HCA Holdings, Inc., excluding losses on sales of facilities, impairments of long-lived assets, loss on retirement of debt and termination of management agreement and Adjusted EBITDA are not measures of financial performance under accounting principles generally accepted in the United States, and should not be considered as alternatives to net income attributable to HCA Holdings, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Holdings, Inc., excluding losses on sales of facilities, impairments of long-lived assets, loss on retirement of debt and termination of management agreement and Adjusted EBITDA are not measurements determined in accordance with generally accepted accounting principles and are susceptible to varying calculations, net income attributable to HCA Holdings, Inc., excluding losses on sales of facilities, impairments of long-lived assets, loss on retirement of debt and termination of management agreement and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies. |
S-46
Table of Contents
Supplemental Non-GAAP Disclosures
Operating Measures on a Cash Revenues Basis
Second Quarter
(Dollars in millions)
2011 | 2010 | |||||||||||||||||||||||
Non-GAAP | Non-GAAP | |||||||||||||||||||||||
% of Cash | GAAP% of | % of Cash | GAAP% of | |||||||||||||||||||||
Revenues | Revenues | Revenues | Revenues | |||||||||||||||||||||
Amount | Ratios(b) | Ratios(b) | Amount | Ratios(b) | Ratios(b) | |||||||||||||||||||
Revenues | $ | 8,063 | 100.0 | $ | 7,756 | 100.0 | ||||||||||||||||||
Provision for doubtful accounts | 775 | 788 | ||||||||||||||||||||||
Cash revenues(a) | 7,288 | 100.0 | 6,968 | 100.0 | ||||||||||||||||||||
Salaries and benefits | 3,320 | 45.5 | 41.2 | 3,076 | 44.1 | 39.6 | ||||||||||||||||||
Supplies | 1,295 | 17.8 | 16.1 | 1,251 | 17.9 | 16.1 | ||||||||||||||||||
Other operating expenses | 1,326 | 18.2 | 16.4 | 1,226 | 17.7 | 15.9 | ||||||||||||||||||
% changes from prior year: | ||||||||||||||||||||||||
Revenues | 4.0 | % | ||||||||||||||||||||||
Cash revenues | 4.6 | |||||||||||||||||||||||
Revenue per equivalent admission | 0.5 | |||||||||||||||||||||||
Cash revenue per equivalent admission | 1.1 |
(a) | Cash revenues is defined as reported revenues less the provision for doubtful accounts. We use cash revenues as an analytical indicator for purposes of assessing the effect of uninsured patient volumes, adjusted for the effect of both the revenue deductions related to uninsured accounts (charity care and uninsured discounts) and the provision for doubtful accounts (which relates primarily to uninsured accounts), on our revenues and certain operating expenses, as a percentage of cash revenues. During the second quarter of 2011, charity care increased $58 million, uninsured discounts increased $270 million and the provision for doubtful accounts declined $13 million, compared to the second quarter of 2010. Cash revenues is commonly used as an analytical indicator within the health care industry. Cash revenues should not be considered as a measure of financial performance under generally accepted accounting principles (“GAAP”). Because cash revenues is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, cash revenues, as presented, may not be comparable to other similarly titled measures of other health care companies. | |
(b) | Salaries and benefits, supplies and other operating expenses, as a percentage of cash revenues (a non-GAAP financial measure), present the impact on these ratios due to the adjustment of deducting the provision for doubtful accounts from reported revenues and results in these ratios being non-GAAP financial measures. We believe these non-GAAP financial measures are useful to investors to provide disclosures of our results of operations on the same basis as that used by management. Management uses this information to compare certain operating expense categories as a percentage of cash revenues. Management finds this information useful to evaluate certain expense category trends without the influence of whether adjustments related to revenues for uninsured accounts are recorded as revenue adjustments (charity care and uninsured discounts) or operating expenses (provision for doubtful accounts), and thus the expense category trends are generally analyzed as a percentage of cash revenues. These non-GAAP financial measures should not be considered alternatives to GAAP financial measures. We believe this supplemental information provides management and the users of our financial statements with useful information forperiod-to-period comparisons. Investors are encouraged to use GAAP measures when evaluating our overall financial performance. |
S-47
Table of Contents
Supplemental Non-GAAP Disclosures
Operating Measures on a Cash Revenues Basis
For the Six Months Ended June 30, 2011 and 2010
(Dollars in millions)
2011 | 2010 | |||||||||||||||||||||||
Non-GAAP | Non-GAAP | |||||||||||||||||||||||
% of Cash | GAAP% of | % of Cash | GAAP% of | |||||||||||||||||||||
Revenues | Revenues | Revenues | Revenues | |||||||||||||||||||||
Amount | Ratios(b) | Ratios(b) | Amount | Ratios(b) | Ratios(b) | |||||||||||||||||||
Revenues | $ | 16,118 | 100.0 | $ | 15,300 | 100.0 | ||||||||||||||||||
Provision for doubtful accounts | 1,424 | 1,352 | ||||||||||||||||||||||
Cash revenues(a) | 14,694 | 100.0 | 13,948 | 100.0 | ||||||||||||||||||||
Salaries and benefits | 6,615 | 45.0 | 41.0 | 6,148 | 44.1 | 40.2 | ||||||||||||||||||
Supplies | 2,570 | 17.5 | 15.9 | 2,451 | 17.6 | 16.0 | ||||||||||||||||||
Other operating expenses | 2,648 | 18.0 | 16.5 | 2,428 | 17.3 | 15.9 | ||||||||||||||||||
% changes from prior year: | ||||||||||||||||||||||||
Revenues | 5.3 | % | ||||||||||||||||||||||
Cash revenues | 5.3 | |||||||||||||||||||||||
Revenue per equivalent admission | 1.7 | |||||||||||||||||||||||
Cash revenue per equivalent admission | 1.7 |
(a) | Cash revenues is defined as reported revenues less the provision for doubtful accounts. We use cash revenues as an analytical indicator for purposes of assessing the effect of uninsured patient volumes, adjusted for the effect of both the revenue deductions related to uninsured accounts (charity care and uninsured discounts) and the provision for doubtful accounts (which relates primarily to uninsured accounts), on our revenues and certain operating expenses, as a percentage of cash revenues. During the first six months of 2011, charity care increased $148 million, uninsured discounts increased $508 million and the provision for doubtful accounts increased $72 million, compared to the first six months of 2010. Cash revenues is commonly used as an analytical indicator within the health care industry. Cash revenues should not be considered as a measure of financial performance under generally accepted accounting principles (“GAAP”). Because cash revenues is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, cash revenues, as presented, may not be comparable to other similarly titled measures of other health care companies. | |
(b) | Salaries and benefits, supplies and other operating expenses, as a percentage of cash revenues (a non-GAAP financial measure), present the impact on these ratios due to the adjustment of deducting the provision for doubtful accounts from reported revenues and results in these ratios being non-GAAP financial measures. We believe these non-GAAP financial measures are useful to investors to provide disclosures of our results of operations on the same basis as that used by management. Management uses this information to compare certain operating expense categories as a percentage of cash revenues. Management finds this information useful to evaluate certain expense category trends without the influence of whether adjustments related to revenues for uninsured accounts are recorded as revenue adjustments (charity care and uninsured discounts) or operating expenses (provision for doubtful accounts), and thus the expense category trends are generally analyzed as a percentage of cash revenues. These non-GAAP financial measures should not be considered alternatives to GAAP financial measures. We believe this supplemental information provides management and the users of our financial statements with useful information forperiod-to-period comparisons. Investors are encouraged to use GAAP measures when evaluating our overall financial performance. |
S-48
Table of Contents
• | $7.554 billion-equivalent in term loan facilities, comprised of a $487 million senior secured term loanA-1 facility maturing on November 17, 2012, a $594 million senior secured term loanA-2 facility maturing on May 2, 2016, a $1.689 billion senior secured term loan B-1 facility maturing on November 17, 2013, a $2.000 billion senior secured term loan B-2 facility maturing on March 31, 2017, a $2.373 billion senior secured term loan B-3 facility maturing on May 1, 2018 and a €291 million, or $411 million-equivalent, senior secured European term loan facility maturing on November 17, 2013; and |
• | $4.000 billion in revolving credit facilities, comprised of a $2.000 billion senior secured asset-based revolving credit facility available in dollars maturing on November 16, 2012 and a $2.000 billion senior secured revolving credit facility available in dollars, euros and pounds sterling currently maturing on November 17, 2015. Availability under the asset-based revolving credit facility is subject to a borrowing base of 85% of eligible accounts receivable less customary reserves. |
S-49
Table of Contents
• | As to refinancing term loans, (1) the proceeds from such refinancing term loans be used to repay in full the initial term loans before being used to repay any previously issued refinancing term loans; (2) the refinancing term loans mature no earlier than the latest maturity date of any of the initial term loans; (3) the weighted average life to maturity for the refinancing term loans be no shorter than the remaining weighted average life to maturity of the tranche B term loan under the cash flow credit facility measured at the time such refinancing term loans are incurred; and (4) refinancing term loans will not share in mandatory prepayments resulting from the creation or issuance of extended term loansand/or first lien notes until the initial term loans are repaid in full but will share in other mandatory prepayments such as those from asset sales. |
S-50
Table of Contents
• | As to replacement revolvers, terms of such replacement revolver be substantially identical to the commitments being replaced, other than with respect to maturity, size of any swingline loanand/or letter of credit subfacilities and pricing. |
• | As to extended term loans, (1) any offer to extend must be made to all lenders under the term loan being extended, and, if such offer is oversubscribed, the extension will be allocated ratably to the lenders according to the respective amounts then held by the accepting lenders; (2) each series of extended term loans having the same interest margins, extension fees and amortization schedule shall be a separate class of term loans; and (3) extended term loans will not share in mandatory prepayments resulting from the creation or issuance of refinancing term loansand/or first lien notes until the initial term loans are repaid in full but will share in other mandatory prepayments such as those from asset sales. |
• | Any refinancing term loans and any obligations under replacement revolvers will have apari passu claim on the collateral securing the initial term loans and the initial revolver. |
S-51
Table of Contents
• | 50% (which percentage will be reduced to 25% if HCA Inc.’s total leverage ratio is 5.50x or less and to 0% if HCA Inc.’s total leverage ratio is 5.00x or less) of HCA Inc.’s annual excess cash flow; |
S-52
Table of Contents
• | 100% of the compensation for any casualty event, proceeds from permitted sale-leasebacks and the net cash proceeds of all nonordinary course asset sales or other dispositions of property, other than the Receivables Collateral, as defined below, if HCA Inc. does not (1) reinvest or commit to reinvest those proceeds in assets to be used in our business or to make certain other permitted investments within 15 months as long as, in the case of any such commitment to reinvest or make certain other permitted investments, such investment is completed within such15-month period or, if later, within 180 days after such commitment is made or (2) apply such proceeds within 15 months to repay debt of HCA Inc. that was outstanding on the effective date of the Recapitalization scheduled to mature prior to the earliest final maturity of the senior secured credit facilities then outstanding; and |
• | 100% of the net cash proceeds of any incurrence of debt, other than proceeds from the receivables facilities and other debt permitted under the senior secured credit facilities. |
• | the term loanA-1 facility amortizes in quarterly installments such that the aggregate amount of the original funded principal amount of such facility repaid pursuant to such amortization payments in each year, with the quarter ending June 30, 2011, is equal to $14.68 million in the first quarter, $57.39 million in the following two quarters, $215.20 million in the following three quarters and with the balance being payable on the final maturity date of such term loans; |
• | the term loanA-2 facility amortizes in equal quarterly installments that commenced on June 30, 2011 in aggregate annual amounts equal to 1.25% of the amount outstanding, on the restatement effective date of such facility, with the balance being payable on the final maturity date of such term loans; |
S-53
Table of Contents
• | each of the term loan B-1 facility and the European term loan facility currently has no remaining amortization payments,with the balance being payable on the final maturity date of such term loans; |
• | the term loan B-2 facility amortizes in equal quarterly installments commencing December 31, 2013 in aggregate annual amounts equal to $5 million, with the balance payable on the final maturity date of such term loans; and |
• | the term loan B-3 facility amortizes in equal quarterly installments commencing December 31, 2013 in aggregate annual amounts equal to 0.25% of the amount outstanding, on the restatement effective date of such facility, with the balance being payable on the final maturity date of such term loans. |
• | a first-priority lien on the capital stock owned by HCA Inc. or by any U.S. guarantor in each of their respective first-tier subsidiaries (limited, in the case of foreign subsidiaries, to 65% of the voting stock of such subsidiaries); |
• | a first-priority lien on substantially all present and future assets of HCA Inc. and of each U.S. guarantor other than (i) “Principal Properties” (as defined in the 1993 Indenture), except for certain “Principal Properties” the aggregate amount of indebtedness secured thereby in respect of the cash flow credit facility and the first lien notes and any future first lien obligations, taken as a whole, do not exceed 10% of “Consolidated Net Tangible Assets” (as defined under the 1993 Indenture), (ii) certain other real properties and (iii) deposit accounts, other bank or securities accounts, cash, leaseholds, motor-vehicles and certain other exceptions (such collateral under this and the preceding bullet, the “Non-Receivables Collateral”); and |
• | a second-priority lien on certain of the Receivables Collateral (such portion of the Receivables Collateral, the “Shared Receivables Collateral”; the Receivables Collateral that does not secure |
S-54
Table of Contents
such cash flow credit facility on a second-priority basis is referred to as the “Separate Receivables Collateral”). |
• | incur additional indebtedness; |
• | create liens; |
• | enter into sale and leaseback transactions; |
• | engage in mergers or consolidations; |
• | sell or transfer assets; |
• | pay dividends and distributions or repurchase capital stock; |
• | make investments, loans or advances; |
• | with respect to the asset-based revolving credit facility, prepay certain subordinated indebtedness, the second lien notes and certain other indebtedness existing on the effective date of the Recapitalization (“Retained Indebtedness”), subject to certain exceptions; |
• | make certain acquisitions; |
• | engage in certain transactions with affiliates; |
• | make certain material amendments to agreements governing certain subordinated indebtedness, the second lien notes or Retained Indebtedness; and |
• | change lines of business. |
• | in the case of the asset-based revolving credit facility, a minimum interest coverage ratio (applicable only when availability under such facility is less than 10% of the borrowing base thereunder); and |
• | in the case of the other senior secured credit facilities, a maximum total leverage ratio. |
S-55
Table of Contents
• | $1.500 billion aggregate principal amount of 81/2% senior secured notes due 2019 issued on April 22, 2009 at a price of 96.755% of their face value, resulting in $1.451 billion of gross proceeds; |
• | $1.250 billion aggregate principal amount of 77/8% senior secured notes due 2020 issued on August 11, 2009 at a price of 98.254% of their face value, resulting in $1.228 billion of gross proceeds; and |
• | $1.400 billion aggregate principal amount of 71/4% senior secured first lien notes due 2020 issued on March 10, 2010 at a price of 99.095% of their face value, resulting in $1.387 billion of gross proceeds. |
• | $1.000 billion aggregate principal amount of 91/8% second lien notes due 2014; |
• | $3.200 billion aggregate principal amount of 91/4% second lien notes due 2016; |
• | $1.578 billion aggregate principal amount of 95/8% cash/103/8%pay-in-kind second lien toggle notes due 2016, which toggle notes allow us, at HCA Inc.’s option, to pay interest in-kind during the first five years at the higher interest rate of 103/8%. HCA Inc. elected in November 2008 to pay interest in-kind in the amount of $78 million for the interest period ending in May 2009; and |
• | $310 million aggregate principal amount of 97/8% senior secured notes due 2017. |
S-56
Table of Contents
• | incur additional debt or issue certain preferred stock; |
• | pay dividends on or make certain distributions of our capital stock or make other restricted payments; |
• | create certain liens or encumbrances; |
• | sell certain assets; |
• | enter into certain transactions with affiliates; |
• | make certain investments; and |
• | consolidate, merge, sell or otherwise dispose of all or substantially all of our assets. |
S-57
Table of Contents
• | $402,499,000 aggregate principal amount of 6.95% Senior Notes due 2012; |
• | $500,000,000 aggregate principal amount of 6.30% Senior Notes due 2012; |
• | $500,000,000 aggregate principal amount of 6.25% Senior Notes due 2013; |
• | $500,000,000 aggregate principal amount of 6.75% Senior Notes due 2013; |
• | $500,000,000 aggregate principal amount of 5.75% Senior Notes due 2014; |
• | $750,000,000 aggregate principal amount of 6.375% Senior Notes due 2015; |
• | $1,000,000,000 aggregate principal amount of 6.50% Senior Notes due 2016; |
• | $291,436,000 aggregate principal amount of 7.69% Senior Notes due 2025; |
• | $250,000,000 aggregate principal amount of 7.50% Senior Notes due 2033; |
• | $150,000,000 aggregate principal amount of 7.19% Debentures due 2015; |
• | $135,645,000 aggregate principal amount of 7.50% Debentures due 2023; |
• | $150,000,000 aggregate principal amount of 8.36% Debentures due 2024; |
• | $150,000,000 aggregate principal amount of 7.05% Debentures due 2027; |
• | $100,000,000 aggregate principal amount of 7.75% Debentures due 2036; and |
• | $200,000,000 aggregate principal amount of 7.50% Debentures due 2095. |
S-58
Table of Contents
• | assume or guarantee indebtedness or obligation secured by mortgages, liens, pledges or other encumbrances; |
• | enter into sale and lease-back transactions with respect to any “Principal Property” (as such term is defined in the 1993 Indenture); |
• | create, incur, issue, assume or otherwise become liable with respect to, extend the maturity of, or become responsible for the payment of, any debt or preferred stock; and |
• | consolidate, merge, sell or otherwise dispose of all or substantially all of HCA Inc.’s assets. |
S-59
Table of Contents
• | create liens on certain assets to secure debt; |
• | enter into certain sale and lease-back transactions; and |
• | consolidate, merge, sell or otherwise dispose of all or substantially all of HCA Holdings, Inc.’s assets. |
S-60
Table of Contents
• | will be general senior obligations of the Issuer; |
• | will be secured on a first-priority basis, equally and ratably with all existing and future obligations of the Issuer and the Guarantors under any existing and future First Lien Obligations, by all of the assets of the Issuer and the Guarantors which secure the General Credit Facility (other than the European Collateral), subject to the Liens securing the Issuer’s and the Guarantors’ ABL Obligations and other Permitted Liens; |
• | will be secured on a second-priority basis, equally and ratably with all existing and future obligations of the Issuer and the Guarantors under any existing and future First Lien Obligations, by all of the assets of the Issuer and the Guarantors securing the ABL Facility which also secure the General Credit Facility, subject to the Liens securing the Issuer’s and the Guarantors’ ABL Obligations and other Permitted Liens; |
• | will be effectively subordinated to the Issuer’s and the Guarantors’ obligations under the ABL Facility, to the extent of the value of the Shared Receivables Collateral; |
S-61
Table of Contents
• | will be effectively subordinated to any obligations secured by Permitted Liens, to the extent of the value of the assets of the Issuer and the Guarantors subject to those Permitted Liens; |
• | will be structurally subordinated to any existing and future indebtedness and liabilities of non-guarantor Subsidiaries, including the ABL Financing Entities and the Issuer’s Foreign Subsidiaries and any Unrestricted Subsidiaries and including indebtedness under the Company’s senior secured European term loan facility included in the General Credit Facility; |
• | will rank equally in right of payment with all existing and future senior Indebtedness of the Issuer and the Guarantors but, to the extent of the value of the Collateral, will be effectively senior to all of the Issuer’s and the Guarantors’ unsecured senior Indebtedness (including the Existing Notes) and Junior Lien Obligations (including the Existing Second Priority Notes); |
• | will be senior in right of payment to any future Subordinated Indebtedness (as defined with respect to the Notes) of the Issuer; and |
• | will be initially unconditionally guaranteed on a joint and several and senior basis by each Restricted Subsidiary that guarantees the General Credit Facility (other than any Foreign Subsidiary). |
• | the unsecured obligation of Holdings (in such capacity, the“Parent Guarantor”); |
• | equal in right of payment to with all of the Parent Guarantor’s existing and future indebtedness that is not subordinated in right of payment to its Parent Guarantee (including the Parent Guarantor’s existing 73/4% senior notes due 2021 and the guarantees given by the Parent Guarantor in favor of the Unsecured Notes); |
• | senior in right of payment to any future Subordinated Indebtedness of the Parent Guarantor; |
• | effectively subordinated in right of payment to all of the Parent Guarantor’s future indebtedness that is secured by Liens on its assets, to the extent of the value of the assets securing such indebtedness; and |
• | structurally subordinated in right of payment to all Indebtedness of the Parent Guarantor’s Subsidiaries (other than the Issuer). |
S-62
Table of Contents
S-63
Table of Contents
S-64
Table of Contents
S-65
Table of Contents
S-66
Table of Contents
S-67
Table of Contents
S-68
Table of Contents
S-69
Table of Contents
S-70
Table of Contents
S-71
Table of Contents
S-72
Table of Contents
• | selling or otherwise disposing of, in any transaction or series of related transactions, any property subject to the Lien of the Security Documents that has become worn out, defective, obsolete or not used or useful in the business; |
• | abandoning, terminating, canceling, releasing or making alterations in or substitutions of any leases or contracts subject to the Lien of the Indenture or any of the Security Documents; |
• | surrendering or modifying any franchise, license or permit subject to the Lien of the Security Documents that it may own or under which it may be operating; |
S-73
Table of Contents
• | altering, repairing, replacing, changing the location or position of and adding to its structures, machinery, systems, equipment, fixtures and appurtenances; |
• | granting a license of any intellectual property; |
• | selling, transferring or otherwise disposing of inventory in the ordinary course of business; |
• | collecting accounts receivable in the ordinary course of business as permitted by the covenant described under “—Repurchase at the option of holders—Asset sales”; |
• | making cash payments (including for the repayment of Indebtedness or interest) from cash that is at any time part of the Collateral in the ordinary course of business that are not otherwise prohibited by the Indenture and the Security Documents; and |
• | abandoning any intellectual property that is no longer used or useful in the Issuer’s business. |
S-74
Table of Contents
S-75
Table of Contents
S-76
Table of Contents
S-77
Table of Contents
• | 100% of the aggregate principal amount of the Notes to be redeemed, and |
• | an amount equal to sum of the present value of the remaining scheduled payments of principal of and interest on the Notes to be redeemed (excluding accrued and unpaid interest to the redemption date and subject to the right of Holders on the relevant record date to receive interest due on the relevant interest payment date) discounted from their scheduled date of payment to the redemption date on a semi-annual basis (assuming a360-day year consisting of twelve30-day months) using a discount rate equal to the Treasury Rate plus 50 basis points |
• | plus, in each of the above cases, accrued and unpaid interest, if any, to such redemption date. |
S-78
Table of Contents
S-79
Table of Contents
S-80
Table of Contents
S-81
Table of Contents
S-82
Table of Contents
S-83
Table of Contents
S-84
Table of Contents
S-85
Table of Contents
S-86
Table of Contents
S-87
Table of Contents
S-88
Table of Contents
• | failure to pay the principal or any premium on the Notes when due; |
• | failure to pay any interest on the Notes when due, and such default continues for a period of 30 days; |
• | failure to deposit any sinking fund payment in respect of the Notes when due; |
• | failure to perform, or the breach of, any of our other applicable covenants or warranties in the Indenture, and such default continues for a period of 60 days after written notice by Holders of at least 10% in principal amount of the outstanding Notes; |
• | events in bankruptcy, insolvency or reorganization; |
• | the Guarantee of any Significant Subsidiary shall for any reason cease to be in full force and effect or be declared null and void or any responsible officer of any Guarantor that is a Significant Subsidiary, as the case may be, denies that it has any further liability under its Guarantee or gives notice to such effect, other than by reason of the termination of the Indenture or the release of any such Guarantee in accordance with the Indenture; or |
• | to the extent applicable, with respect to any Collateral having a fair market value in excess of $200 million, individually or in the aggregate, (a) the security interest under the Security Documents, at any time, ceases to be in full force and effect for any reason other than in accordance with the terms of the Indenture, the Security Documents and the Intercreditor |
S-89
Table of Contents
Agreements, (b) any security interest created thereunder or under the Indenture is declared invalid or unenforceable by a court of competent jurisdiction or (c) the Issuer or any Guarantor asserts, in any pleading in any court of competent jurisdiction, that any such security interest is invalid or unenforceable. |
S-90
Table of Contents
S-91
Table of Contents
• | the successor entity assumes the Issuer’s obligations on the Notes and under the Indenture, as if such successor were an original party to the Indenture; |
• | after giving effect to the transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred and be continuing; |
• | if, as a result of any such consolidation or merger or such conveyance, transfer or lease, properties or assets of the Issuer would become subject to a mortgage, pledge, lien, security interest or other encumbrance that would not be permitted by the Indenture, the Issuer or such successor corporation or Person, as the case may be, shall take such steps as shall be necessary effectively to secure all the Notes equally and ratably with (or prior to) all indebtedness secured thereby; |
• | each Guarantor, unless it is the other party to the transactions described above, shall have by supplemental indenture confirmed that its Guarantee shall apply to such Person’s obligations under the Indenture and the Notes; |
• | the Collateral owned by the successor entity will (a) continue to constitute Collateral under the Indenture and the Security Documents, (b) be subject to a Lien in favor of the First Lien Collateral Agent for the benefit of the Trustee and the Holders of the Notes and (c) not be subject to any other Lien, other than Permitted Liens and other Liens permitted under the covenant described under “—Liens”; |
S-92
Table of Contents
• | to the extent any assets of the Person which is merged or consolidated with or into the successor entity are assets of the type which would constitute Collateral under the Security Documents, the successor entity will take such action as may be reasonably necessary to cause such property and assets to be made subject to the Lien of the Security Documents in the manner and to the extent required in the Indenture or any of the Security Documents and shall take all reasonably necessary action so that such Lien is perfected to the extent required by the Security Documents; and |
• | the Issuer has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel each stating that such consolidation, merger, conveyance, transfer or lease and such supplemental indenture comply with this covenant and that all conditions precedent provided for relating to such transaction have been complied with. |
S-93
Table of Contents
S-94
Table of Contents
S-95
Table of Contents
S-96
Table of Contents
S-97
Table of Contents
S-98
Table of Contents
S-99
Table of Contents
S-100
Table of Contents
S-101
Table of Contents
S-102
Table of Contents
S-103
Table of Contents
S-104
Table of Contents
S-105
Table of Contents
S-106
Table of Contents
S-107
Table of Contents
S-108
Table of Contents
S-109
Table of Contents
S-110
Table of Contents
S-111
Table of Contents
S-112
Table of Contents
S-113
Table of Contents
S-114
Table of Contents
S-115
Table of Contents
S-116
Table of Contents
S-117
Table of Contents
S-118
Table of Contents
S-119
Table of Contents
S-120
Table of Contents
S-121
Table of Contents
S-122
Table of Contents
S-123
Table of Contents
S-124
Table of Contents
• | unsecured senior obligations of the Issuer; |
• | equal in right of payment to any future senior Indebtedness of the Issuer; |
• | senior in right of payment to any future Subordinated Indebtedness of the Issuer; |
• | structurally subordinated in right of payment to all Indebtedness of the Issuer’s Subsidiaries; and |
• | guaranteed on a senior unsecured basis by the Parent Guarantor. |
S-125
Table of Contents
• | the unsecured obligation of the Parent Guarantor; |
• | equal in right of payment to with all of the Parent Guarantor’s existing and future indebtedness that is not subordinated in right of payment to its Parent Guarantee (including the Parent Guarantor’s existing 73/4% senior notes due 2021 and the guarantees given by the Parent Guarantor in favor of the Secured Notes); |
• | senior in right of payment to any future Subordinated Indebtedness of the Parent Guarantor; |
• | effectively subordinated in right of payment to any of the Parent Guarantor’s future indebtedness that is secured by Liens on its assets to the extent of the value of the assets securing such indebtedness; and |
• | structurally subordinated in right of payment to all Indebtedness of the Parent Guarantor’s Subsidiaries (other than the Issuer). |
S-126
Table of Contents
• | 100% of the aggregate principal amount of the Notes to be redeemed, and |
• | an amount equal to sum of the present value of the remaining scheduled payments of principal of and interest on the Notes to be redeemed (excluding accrued and unpaid interest to the redemption date and subject to the right of Holders on the relevant record date to receive interest due on the relevant interest payment date) discounted from their scheduled date of payment to the redemption date on a semi-annual basis (assuming a360-day year consisting of twelve30-day months) using a discount rate equal to the Treasury Rate plus 50 basis points |
• | plus, in each of the above cases, accrued and unpaid interest, if any, to such redemption date. |
S-127
Table of Contents
S-128
Table of Contents
S-129
Table of Contents
S-130
Table of Contents
S-131
Table of Contents
S-132
Table of Contents
• | failure to pay the principal or any premium on the Notes when due; |
• | failure to pay any interest on the Notes when due, and such default continues for a period of 30 days; |
• | failure to deposit any sinking fund payment in respect of the Notes when due; |
• | failure to perform, or the breach of, any of our other applicable covenants or warranties in the Indenture, and such default continues for a period of 60 days after written notice by Holders of at least 10% in principal amount of the outstanding Notes; or |
• | events in bankruptcy, insolvency or reorganization. |
S-133
Table of Contents
S-134
Table of Contents
• | In the case of the Issuer, the successor entity assumes the Issuer’s obligations on the Notes and under the Indenture, as if such successor were an original party to the Indenture; |
• | in the case of the Parent Guarantor, the successor entity assumes the Parent Guarantor’s obligations under the Indenture and the Parent Guarantee, as if such successor were an original party to the Indenture and such Parent Guarantee; |
• | after giving effect to the transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred and be continuing; |
S-135
Table of Contents
• | if, as a result of any such consolidation or merger or such conveyance, transfer or lease, properties or assets of the Issuer or the Parent Guarantor, as applicable, would become subject to a mortgage, pledge, lien, security interest or other encumbrance that would not be permitted by the Indenture, the Issuer or the Parent Guarantor, as applicable, or such successor corporation or Person, as the case may be, shall take such steps as shall be necessary effectively to secure all the Notes or the Parent Guarantee, as applicable, equally and ratably with (or prior to) all indebtedness secured thereby; and |
• | the Issuer or the Parent Guarantor, as the case may be, has delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel each stating that such consolidation, merger, conveyance, transfer or lease and such supplemental indenture comply with this covenant and that all conditions precedent provided for relating to such transaction have been complied with. |
S-136
Table of Contents
S-137
Table of Contents
S-138
Table of Contents
S-139
Table of Contents
S-140
Table of Contents
S-141
Table of Contents
S-142
Table of Contents
S-143
Table of Contents
• | an individual who is a citizen or resident of the United States; |
• | a corporation (or any other entity treated as a corporation for United States federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia; |
• | an estate the income of which is subject to United States federal income taxation regardless of its source; or |
• | a trust if it (1) is subject to the primary supervision of a court within the United States and one or more United States persons have the authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable United States Treasury regulations to be treated as a United States person. |
• | a dealer in securities or currencies; |
• | a financial institution; |
• | a regulated investment company; |
• | a real estate investment trust; |
• | a tax-exempt organization; |
• | an insurance company; |
• | a U.S. holder that makes a special election to treat all stated interest on the notes as original issue discount (“OID”); |
S-144
Table of Contents
• | a person holding the notes as part of a hedging, integrated, conversion or constructive sale transaction or a straddle; |
• | a trader in securities that has elected themark-to-market method of accounting for your securities; |
• | a person liable for alternative minimum tax; |
• | a partnership or other pass-through entity for United States federal income tax purposes (or an investor in such entities); |
• | a U.S. holder whose “functional currency” is not the U.S. dollar; |
• | a “controlled foreign corporation”; |
• | a “passive foreign investment company”; or |
• | a United States expatriate. |
S-145
Table of Contents
• | the note’s “adjusted issue price” at the beginning of the accrual period multiplied by its yield to maturity, determined on the basis of compounding at the close of each accrual period and properly adjusted for the length of the accrual period, over |
• | the aggregate of all qualified stated interest allocable to the accrual period. |
• | it is payable at least once per year; |
• | it is payable over the entire term of the note; and |
• | it is payable at a single fixed rate or, subject to certain conditions, based on one or more interest indices. |
S-146
Table of Contents
• | interest paid on the notes is not effectively connected with your conduct of a trade or business in the United States; |
• | you do not actually (or constructively) own 10% or more of the total combined voting power of all classes of our voting stock within the meaning of the Code and applicable United States Treasury regulations; |
• | you are not a controlled foreign corporation that is related to us actually or constructively through stock ownership; |
• | you are not a bank whose receipt of interest on the notes is described in Section 881(c)(3)(A) of the Code; and |
• | either (a) you provide your name and address on an IRSForm W-8BEN (or other applicable form), and certify, under penalties of perjury, that you are not a United States person as defined under the Code or (b) you hold your notes through certain foreign intermediaries and satisfy the certification requirements of applicable United States Treasury regulations. Special certification rules apply tonon-U.S. holders that are pass-through entities rather than corporations or individuals. |
• | IRSForm W-8BEN (or other applicable form) certifying an exemption from or reduction in withholding under the benefit of an applicable income tax treaty; or |
• | IRSForm W-8ECI (or other applicable form) certifying interest paid on the notes is not subject to withholding tax because it is effectively connected with your conduct of a trade or business in the United States (as discussed below under “—United States Federal Income Tax”). |
S-147
Table of Contents
• | the gain is effectively connected with your conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to a United States permanent establishment), in which case you will be taxed in the same manner as discussed above with respect to effectively connected interest; or |
• | you are an individual who is present in the United States for 183 days or more in the taxable year of that disposition, and certain other conditions are met, in which case you will be subject to a flat 30% United States federal income tax on any gain recognized (except as otherwise provided by an applicable income tax treaty), which may be offset by certain United States source losses. |
S-148
Table of Contents
S-149
Table of Contents
S-150
Table of Contents
S-151
Table of Contents
Principal amount of | Principal amount of | |||||||
Underwriter | secured notes | unsecured notes | ||||||
J.P. Morgan Securities LLC | $ | $ | ||||||
Barclays Capital Inc. | $ | $ | ||||||
Merrill Lynch, Pierce, Fenner & Smith Incorporated | $ | $ | ||||||
Citigroup Global Markets Inc. | $ | $ | ||||||
Deutsche Bank Securities Inc. | $ | $ | ||||||
Wells Fargo Securities, LLC | $ | $ | ||||||
Total | $ | $ | ||||||
Paid by us | ||||
Per secured note | % | |||
Per unsecured note | % |
• | We will not offer or sell any of our debt securities (other than the notes) for a period of 30 days after the date of this prospectus supplement without the prior consent of J.P. Morgan Securities LLC. |
• | We will pay our expenses related to the offering. |
S-152
Table of Contents
• | We will indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or contribute to payments that the underwriters may be required to make in respect of those liabilities. |
• | to any legal entity which is a qualified investor as defined in the Prospectus Directive; |
• | to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the relevant dealer or dealers nominated by the Company for any such offer; or |
• | in any other circumstances falling within Article 3(2) of the Prospectus Directive, |
S-153
Table of Contents
S-154
Table of Contents
S-155
Table of Contents
S-156
Table of Contents
S-157
Table of Contents
1 | ||||
1 | ||||
1 | ||||
2 | ||||
4 | ||||
5 | ||||
5 | ||||
5 | ||||
6 | ||||
22 | ||||
23 | ||||
23 |
Table of Contents
1
Table of Contents
• | HCA Holdings, Inc.’s Annual Report onForm 10-K for the year ended December 31, 2010(SEC File No. 001-11239); | |
• | HCA Holdings, Inc.’s Quarterly Report onForm 10-Q for the period ended March 31, 2011(SEC File No. 001-11239); | |
• | HCA Holdings, Inc.’s Current Reports onForm 8-K, filed on February 11, 2011, March 16, 2011, April 5, 2011, May 4, 2011, May 9, 2011, July 12, 2011 and July 26, 2011 (other than information furnished pursuant to Item 2.02 or Item 7.01 of any Current Report onForm 8-K, unless expressly stated otherwise therein); and | |
• | All documents filed by HCA Holdings, Inc. under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement and before the termination of the offering to which this prospectus supplement relates (other than information furnished pursuant to Item 2.02 or Item 7.01 of any Current Report on Form8-K, unless expressly stated otherwise therein). |
2
Table of Contents
• | the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms; | |
• | the effects related to the enactment and implementation of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the “Health Reform Law”), the possible enactment of additional federal or state health care reforms and possible changes to the Health Reform Law and other federal, state or local laws or regulations affecting the health care industry; | |
• | increases in the amount and risk of collectibility of uninsured accounts and deductibles and copayment amounts for insured accounts; | |
• | the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services; | |
• | possible changes in the Medicare, Medicaid and other state programs, including Medicaid supplemental payments pursuant to upper payment limit (“UPL”) programs, that may impact reimbursements to health care providers and insurers; | |
• | the highly competitive nature of the health care business; | |
• | changes in revenue mix, including potential declines in the population covered under managed care agreements and the ability to enter into and renew managed care provider agreements on acceptable terms; | |
• | the efforts of insurers, health care providers and others to contain health care costs; | |
• | the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures; | |
• | increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel; | |
• | the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities; | |
• | changes in accounting practices; | |
• | changes in general economic conditions nationally and regionally in our markets; | |
• | future divestitures which may result in charges and possible impairments of long-lived assets; | |
• | changes in business strategy or development plans; | |
• | delays in receiving payments for services provided; | |
• | the outcome of pending and any future tax audits, appeals and litigation associated with our tax positions; | |
• | potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us; | |
• | our ability to demonstrate meaningful use of certified electronic health record technology and recognize revenues for the related Medicare or Medicaid incentive payments; and | |
• | other risk factors described in this prospectus. |
3
Table of Contents
4
Table of Contents
Three Months Ended | Year Ended December 31, | |||||||||||||||||||||||||||
March 31, | March 31, | |||||||||||||||||||||||||||
2011 | 2010 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||||
Ratio of earnings to fixed charges(1) | 1.89 | 2.21 | 1.97 | 1.91 | 1.52 | 1.57 | 2.61 |
(1) | For purposes of calculating the ratio of earnings to fixed charges, earnings represents earnings before income tax expense, and net income attributable to noncontrolling interests, plus fixed charges; and fixed charges include: (a) interest expense; (b) amortization of capitalized expenses related to debt; and (c) the portion of rental expense which management believes is representative of the interest component of rent expense. |
5
Table of Contents
6
Table of Contents
• | the title of the series of debt securities; | |
• | any limit on the aggregate principal amount of debt securities of the series; | |
• | the price or prices at which debt securities of the series will be issued; | |
• | the person to whom any interest on a debt security of the series shall be payable, if other than the person in whose name that debt security is registered on the applicable record date; | |
• | the date or dates on which the applicable issuer will pay the principal of and premium, if any, on debt securities of the series, or the method or methods, if any, used to determine those dates; | |
• | the rate or rates, which may be fixed or variable, at which debt securities of the series will bear interest, if any, or the method or methods, if any, used to determine those rates; | |
• | the basis used to calculate interest, if any, on the debt securities of the series if other than a360-day year of twelve30-day months; | |
• | the date or dates, if any, from which interest on the debt securities of the series will begin to accrue, or the method or methods, if any, used to determine those dates; | |
• | the dates on which the interest, if any, on the debt securities of the series will be payable and the record dates for the payment of interest; | |
• | the place or places where amounts due on the debt securities of the series will be payable and where the debt securities of the series may be surrendered for registration of transfer and exchange, if other than the corporate trust office of the applicable trustee; | |
• | the terms and conditions, if any, upon which the applicable issuer may, at its option, redeem debt securities of the series; | |
• | the terms and conditions, if any, upon which the applicable issuer will repurchase or repay debt securities of the series at the option of the holders of debt securities of the series; | |
• | the terms of any sinking fund or analogous provision; | |
• | if other than U.S. dollars, the currency in which the purchase price for the debt securities of the series will be payable, the currency in which payments on the debt securities of the series will be payable, |
7
Table of Contents
and the ability, if any, of the applicable issuer or the holders of debt securities of the series to have payments made in any other currency or currencies; |
• | any addition to, or modification or deletion of, any covenant or Event of Default with respect to debt securities of the series; | |
• | whether any debt securities of the series will be issued in temporary or permanent global form (“global debt securities”) and, if so, the identity of the depositary for the global debt securities if other than The Depository Trust Company (“DTC”); | |
• | if and under what circumstances the applicable issuer will pay additional amounts (“Additional Amounts”) on the debt securities of the series in respect of specified taxes, assessments or other governmental charges and, if so, whether the applicable issuer will have the option to redeem the debt securities of the series rather than pay the Additional Amounts; | |
• | the extent to which, or the manner in which, any interest payable on a temporary global debt security will be paid, if other than in the manner provided in the indenture; | |
• | the portion of the principal amount of the debt securities of the series which will be payable upon acceleration if other than the full principal amount; | |
• | the authorized denominations in which the debt securities of the series will be issued, if other than denominations of $2,000 and any integral multiples of $1,000; | |
• | the terms, if any, upon which debt securities of the series may be exchangeable for other property; | |
• | if the amount of payments on the debt securities of the series may be determined with reference to an index, formula or other method or methods and the method used to determine those amounts; | |
• | whether the debt securities of the series will be guaranteed by any Guarantors and, if so, the names of the Guarantors of the debt securities of the series and a description of the Guarantees; | |
• | if the debt securities of the series or, if applicable, any Guarantees of those debt securities will be secured by any collateral and, if so, a general description of the collateral and of some of the terms of any related security, pledge or other agreements; | |
• | any listing of the debt securities on any securities exchange; | |
• | any other terms of the debt securities of the series and, if applicable, any Guarantees of the debt securities (whether or not such other terms are consistent or inconsistent with any other terms of the indenture); and | |
• | the appointment of any agents, if other than the applicable trustee. |
8
Table of Contents
• | issue, register the transfer of or exchange debt securities of any series during a period beginning at the opening of business 15 days before any selection of debt securities of that series of like tenor and terms to be redeemed and ending at the close of business on the day of that selection; | |
• | register the transfer of or exchange any registered debt security, or portion of any registered debt security, selected for redemption, except the unredeemed portion of any registered debt security being redeemed in part; or | |
• | issue, register the transfer of or exchange a debt security which has been surrendered for repayment at the option of the holder, except the portion, if any, of the debt security not to be repaid. |
9
Table of Contents
10
Table of Contents
11
Table of Contents
• | a limited-purpose trust company organized under the New York Banking Law; | |
• | a “banking organization” within the meaning of the New York Banking Law; | |
• | a member of the Federal Reserve System; | |
• | a “clearing corporation” within the meaning of the New York Uniform Commercial Code; and | |
• | a “clearing agency” registered pursuant to the provisions of Section 17A of the Securities Exchange Act of 1934. |
12
Table of Contents
• | DTC notifies HCA Holdings, Inc. or HCA Inc., as applicable, that it is unwilling or unable to continue as a depositary for the global debt securities of any series or if DTC ceases to be a clearing agency registered under the Securities Exchange Act of 1934 (if so required by applicable law or regulation) and a successor depositary for the debt securities of such series is not appointed within 90 days of the notification to HCA Holdings, Inc. or HCA Inc., as applicable, or of HCA Holdings, Inc. or HCA Inc., as applicable, becoming aware of DTC’s ceasing to be so registered, as the case may be, | |
• | HCA Holdings, Inc. or HCA Inc., as applicable, determines, in its sole discretion, not to have the debt securities of any series represented by one or more global debt securities, or | |
• | an Event of Default under the applicable indenture has occurred and is continuing with respect to the debt securities of any series, |
13
Table of Contents
14
Table of Contents
15
Table of Contents
• | either (1) HCA Holdings, Inc. or HCA Inc., as applicable, is the surviving corporation or (2) the Person formed by or surviving any such consolidation or merger (if other than HCA Holdings, Inc. or HCA Inc., as applicable,) or to which such sale, assignment, transfer, lease, conveyance or other disposition will have been made is a corporation organized or existing under the laws of the jurisdiction of organization of the applicable issuer or the laws of the United States, any state thereof, the District of Columbia, or any territory thereof (such Person, as the case may be, being herein called the “Successor Company”); | |
• | the Successor Company, if other than the applicable issuer, shall expressly assume all the obligations of the applicable issuer pursuant to supplemental indentures or other documents or instruments in form reasonably satisfactory in form to the trustee; | |
• | immediately after giving effect to the transaction described above, no Event of Default under the applicable indenture, and no event which, after notice or lapse of time or both would become an Event of Default under the applicable indenture, shall have occurred and be continuing; | |
• | with respect to any guaranteed debt securities, each Guarantor, unless it is the other party to the transactions described above, shall have by supplemental indenture confirmed that its Guarantee shall apply to such person’s obligations under the applicable indenture and the debt securities; and | |
• | the trustee shall have received the officers’ certificate and opinion of counsel called for by the applicable indenture. |
16
Table of Contents
17
Table of Contents
• | such holder has previously given written notice to the trustee of a continuing Event of Default with respect to the debt securities of such series; | |
• | the holders of not less than 25% in principal amount of the total outstanding debt securities of such series shall have made written request to the trustee to institute proceedings in respect of such Event of Default in its own name as trustee under the indenture; | |
• | holders have offered to the trustee security or indemnity reasonably satisfactory to the trustee against any loss liability or expense incurred in compliance with such request; | |
• | the trustee has not complied with such request within 60 days after the receipt thereof and the offer of security or indemnity; and | |
• | holders of a majority in principal amount of the total outstanding debt securities have not given the trustee a direction inconsistent with such request within such60-day period. |
• | change the stated maturity of the principal of, or installment of interest, if any, on, any debt securities, or reduce the principal amount thereof or the interest thereon or any premium payable upon redemption thereof; | |
• | change the currency in which the principal of (and premium, if any) or interest on such debt securities are denominated or payable; | |
• | adversely affect the right of repayment or repurchase, if any, at the option of the holder after such obligation arises, or reduce the amount of, or postpone the date fixed for, any payment under any sinking fund or impair the right to institute suit for the enforcement of any payment on or after the stated maturity thereof (or, in the case of redemption, on or after the redemption date); | |
• | reduce the percentage of holders whose consent is required for modification or amendment of the indenture or for waiver of compliance with certain provisions of the indenture or certain defaults; |
18
Table of Contents
• | modify the provisions that require holder consent to modify or amend the indenture or that permit holders to waive compliance with certain provisions of the indenture or certain defaults; | |
• | impair the right of any holder to receive payment of principal of, or interest on such holder’s debt securities on or after the due dates therefor or to institute suit for the enforcement of any payment on or with respect to such holder’s debt securities; or | |
• | except as expressly permitted by the indenture, modify the Guarantees of any Significant Subsidiary in any manner adverse to the holders of any debt securities. |
• | to evidence the succession of another corporation to HCA Holdings, Inc. or HCA Inc., as applicable, or, if applicable, any Guarantor under the applicable indenture and the assumption by such successor of the covenants of HCA Holdings, Inc. or HCA Inc., as applicable, in compliance with the requirements set forth in the indenture; | |
• | to add to the covenants for the benefit of the holders or to surrender any right or power herein conferred upon the HCA Holdings, Inc. or HCA Inc., as applicable; | |
• | to add any additional Events of Default; | |
• | to change or eliminate any of the provisions of the indenture, provided that any such change or elimination shall become effective only when there are no outstanding debt securities of any series created prior to the execution of such supplemental indenture that is entitled to the benefit of such provision and as to which such supplemental indenture would apply; | |
• | to secure the debt securities; | |
• | to supplement any of the provisions of the indenture to such extent necessary to permit or facilitate the defeasance and discharge of the debt securities, provided that any such action does not adversely affect the interests of the holders of the debt securities in any material respect; | |
• | to evidence and provide for the acceptance of appointment hereunder by a successor trustee and to add to or change any of the provisions of the indenture necessary to provide for or facilitate the administration of the trusts by more than one trustee; | |
• | to cure any ambiguity to correct or supplement any provision of the indenture which may be defective or inconsistent with any other provision; | |
• | to change any place or places where the principal of and premium, if any, and interest, if any, on the debt securities shall be payable, the debt securities may be surrendered for registration or transfer, the debt securities may be surrendered for exchange, and notices and demands to or upon HCA Holdings, Inc. or HCA Inc., as applicable, may be served; | |
• | to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act of 1939; | |
• | to conform the text of the indenture or the debt securities to any provision of the section regarding the description of the notes contained in the prospectus supplement to the extent that such provision in such section was intended to be a verbatim recitation of a provision of the indenture or the debt securities; | |
• | to make any amendment to the provisions of the indenture relating to the transfer and legending of debt securities as permitted by the indenture, including, without limitation to facilitate the issuance and administration of the debt securities; provided, however, that (i) compliance with the indenture as so amended would not result in debt securities being transferred in violation of the Securities Act or any |
19
Table of Contents
applicable securities law and (ii) such amendment does not materially and adversely affect the rights of holders to transfer debt securities; or |
• | to add additional Guarantees or additional Guarantors in respect of all or any securities under the indenture, and to evidence the release and discharge of any Guarantor from its obligations under its Guarantee of any or all securities and its obligations under the indenture in respect of any or all Securities in accordance with the terms of the indenture. |
20
Table of Contents
21
Table of Contents
• | to purchasers directly; | |
• | to underwriters for public offering and sale by them; | |
• | through agents; | |
• | through dealers; or | |
• | through a combination of any of the foregoing methods of sale. |
22
Table of Contents
23